Difference between revisions of "IRIS"

Revision as of 14:26, 27 June 2012

This page provides a description and a link to a "IRIS" database that provides information needed when modeling exposure levels or performing exposure assessment.

Short description

IRIS is a database of human health effects that may result from exposure to various substances found in the environment. The heart of the IRIS system is its collection of computer files covering individual chemicals. These chemical files contain descriptive and quantitative information in the following categories: a) Oral reference doses and inhalation reference concentrations (RfDs and RfCs, respectively) for chronic noncarcinogenic health effects, b) Hazard identification, oral slope factors, and oral and inhalation unit risks for carcinogenic effects. Database includes over 500 chemicals.

Long description

http://www.nlm.nih.gov/pubs/factsheets/irisfs.html

Link

http://www.epa.gov/iris/

Key words

human health effects, exposure, toxicology, carcinogenity, hazards

Data scrapping

IRIS database is accessible from this link: http://cfpub.epa.gov/ncea/iris/compare.cfm. The critical data can be obtained at once if all substances and all types of data are selected. A result is an html file with several tables from which the data can be scrapped and transformed into a better format. The January 4th, 2012, version was downloaded from IRIS and saved on this page (see the file below). Who could do this?

Reference system in IRIS database. The number (e.g. 0442) refers to the IRIS chemical identifier.

QuickView
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#reforal  Oral RfDs
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#refinhal Inhalation RfCs
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#woe      Weight-of-Evidence Characterizations
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#quaoral  Oral Slope Factors/Drinking Water Unit Risks
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#quainhal Inhalation Unit Risks

IRIS Summary 
http://www.epa.gov/iris/subst/0442.htm#reforal
http://www.epa.gov/iris/subst/0442.htm#refinhal
http://www.epa.gov/iris/subst/0442.htm#woe
http://www.epa.gov/iris/subst/0442.htm#quaoral
http://www.epa.gov/iris/subst/0442.htm#quainhal

Toxicological Review (PDF)
http://www.epa.gov/iris/toxreviews/0128tr.pdf (this does not exist for many compounds)

Oral RfDs

Oral RfDs were scrapped as an example (chemical starting with A) on Jan 4, 2012.

⇤# : Ei tätä kannata tehdä rivi kerrallaan, vaan ottaa koko viiden taulukon tiedosto (ks. Related files) muokata siitä tekstinkäsittelyohjelmalla viisi t2b-taulukkoa. Etsi-korvaa-toiminnolla voi tehdä suurimman osan muotoiluista. Kannattaa kysyä apua jos ei osaa, koska muuten työssä menee päiviä. --Jouni 10:42, 20 June 2012 (EEST)

⇤#: Huomaa, että IRIS identifier on tärkeä. Se löytyy nettilinkeistä (esim. Acenaphthenen QuickView on tämmöinen linkki: http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#reforal ja siitä näkee, että tämän aineen IRIS identifier on 0442. --Jouni 10:42, 20 June 2012 (EEST)

Difference between revisions of "IRIS"(mg /kg-day)
Obs	Substance	CASRN	Critical Effact(s)	Unit	Oral RfD	Type of RfD	Point of Departure(s)*	Overall Confidence	IRIS identifier
1	Acenaphthene	83-32-9	Hepatotoxicity	mg /kg-day	6 x10-2	NOAEL	175	Low	0442
2	Acenaphthylene	208-96-8	Not Assessed under the IRIS program						0443
3	Acephate	30560-19-1	Inhibition of brain ChE	mg /kg-day	4 x10-3	LEL	0.12	High	0354
4	Acetaldehyde	75-07-0	Not Assessed under the IRIS program						0290
5	Acetochlor	34256-82-1	Salivation, increased ALT and ornithine carbamyl transferase; significant increases in triglyceride and decreased blood glucose levels; histopathological changes in kidneys and testes of males	mg /kg-day	2 x10-2	NOAEL	2 mg/kg-day	High	0521
6	Acetone	67-64-1	Nephropathy	mg /kg-day	0.9	NOAEL	900	Medium	0128
7	Acetonitrile	75-05-8	Information reviewed but value not estimated. Refer to IRIS Summary.						0205
8	Acetophenone	98-86-2	General toxicity	mg /kg-day	1 x10-1	NOAEL	423	Low	0321
9	Acetyl chloride	75-36-5	Not Assessed under the IRIS program						0518
10	Acifluorfen, sodium	62476-59-9	Mortality and kidney lesions	mg /kg-day	1.3 x10-2	NOEL	1.25	Medium	0192
11	Acrolein	107-02-8	Decreased survival	mg /kg-day	5 x10-4	NOAEL	0.05	Medium/High	0364
12	Acrylamide	79-06-1	Degenerative nerve changes	mg /kg-day	0.002	HED (BMDL)	0.053	Medium/High	0286
13	Acrylic acid	79-10-7	Reduced pup weight	mg /kg-day	5 x10-1	NOAEL	53	High	0002
14	Acrylonitrile	107-13-1	Not Assessed under the IRIS program						0206
15	Adiponitrile	111-69-3	Not Assessed under the IRIS program						0515
16	Alachlor	15972-60-8	Hemosiderosis, hemolytic anemia	mg /kg-day	1 x10-2	NOAEL	1	High	0129
17	Alar	1596-84-5	No adverse effects	mg /kg-day	1.5 x10-1	NOEL	15	Low	0287
18	Aldicarb	116-06-3	Sweating as clinical sign of AChe inhibition (other effect: Clinical signs and symptoms of acetylcholinesterase inhibition including sweating, pinpoint pupils, leg weakness, and other effects Nausea, diarrhea, and other signs and symptoms)	mg /kg-day	1 x10-3	NOAEL	0.01	Medium	0003
19	Aldicarb sulfone	1646-88-4	Brain ChE inhibition in females	mg /kg-day	1 x10-3	NOAEL	0.11	Medium	0312
20	Aldrin	309-00-2	Liver toxicity	mg /kg-day	3 x10-5	LOAEL	0.025	Medium	0130
21	Ally	74223-64-6	Decreased body weight	mg /kg-day	2.5 x10-1	NOEL	25	High	0288
22	Allyl alcohol	107-18-6	Impaired renal function and increased liver and kidney weights	mg /kg-day	5 x10-3	NOEL	4.8	Low	0004
23	Allyl chloride	107-05-1	Not Assessed under the IRIS program						0387
24	Aluminum phosphide	20859-73-8	Body weight and clinical parameters	mg /kg-day	4 x10-4	NOAEL	0.043	Medium	0005
25	Amdro	67485-29-4	Increased organ weights	mg /kg-day	3 x10-4	NOEL	0.33	High	0207
26	Ametryn	834-12-8	Liver toxicity	mg /kg-day	9 x10-3	NOEL	8.6	Low	0208
27	4-Aminopyridine	504-24-5	Not Assessed under the IRIS program						0440
28	Amitraz	33089-61-1	Increased mean blood sugar concentration; slight hypothermia	mg /kg-day	2.5 x10-3	NOEL	0.25	Medium	0334
29	Ammonia	7664-41-7	Not Assessed under the IRIS program						0422
30	Ammonium acetate	631-61-8	Not Assessed under the IRIS program						0517
31	Ammonium methacrylate	16325-47-6	Not Assessed under the IRIS program						0516
32	Ammonium sulfamate	7773-06-0	Decrease in body weight	mg /kg-day	2 x10-1	NOEL	214.3	Low	0007
33	Aniline	62-53-3	Not Assessed under the IRIS program						0350
34	ortho-Anisidine	90-04-0	Not Assessed under the IRIS program						0610
35	Anthracene	120-12-7	No observed effects	mg /kg-day	3 x10-1	NOEL	1000	Low	0434
36	Antimony	7440-36-0	Longevity, blood glucose, and cholesterol	mg /kg-day	4 x10-4	LOAEL	0.35	Low	0006
37	Antimony trioxide	1309-64-4	Not Assessed under the IRIS program						0676
38	Apollo	74115-24-5	Liver effects; organ weight changes	mg /kg-day	1.3 x10-2	NOEL	1.25	High	0008
39	Aramite	140-57-8	Not Assessed under the IRIS program						0473
40	Aroclor 1016	12674-11-2	Reduced birth weights	mg /kg-day	7 x10-5	NOAEL	0.007	Medium	0462
41	Aroclor 1248	12672-29-6	Information reviewed but value not estimated. Refer to IRIS Summary.						0649
42	Aroclor 1254	11097-69-1	Ocular exudate, inflamed and prominent Meibomian glands, distorted growth of finger and toe nails; decreased antibody (IgG and IgM) response to sheep erythrocytes	mg /kg-day	2 x10-5	LOAEL	0.005	Medium	0389
43	Arsenic, inorganic	7440-38-2	Hyperpigmentation, keratosis and possible vascular complications	mg /kg-day	3 x10-4	NOAEL	0.0008	Medium	0278
44	Arsine	7784-42-1	Not Assessed under the IRIS program						0672
45	Asbestos	1332-21-4	Not Assessed under the IRIS program						0371
46	Assure	76578-14-8	Liver cell enlargement	mg /kg-day	9 x10-3	NOEL	0.9	High	0335
47	Asulam	3337-71-1	Lower ovarian weight, lower liver/body weight	mg /kg-day	5 x10-2	LEL	50	Medium	0284
48	Atrazine	1912-24-9	Decreased body weight gain (other effect: Cardiac toxicity and moderate-to-severe dilation of the right atrium)	mg /kg-day	3.5 x10-2	NOAEL	3.5	High	0209
49	Avermectin B1	65195-55-3	Increased retinal folds in weanlings, decreased viability and lactation indices, decreased pup body weight, increase of dead pups at birth	mg /kg-day	4 x10-4	NOEL	0.12	High	0381
50	Azobenzene	103-33-3	Not Assessed under the IRIS program						0351
51	Barium and Compounds	7440-39-3	Nephropathy	mg /kg-day	0.2	BMDL05	63	Medium	0010
52	Barium cyanide	542-62-1	Information reviewed but value not estimated. Refer to IRIS Summary.						0009
53	Baygon	114-26-1	Mild cholinergic symptoms and RBD ChE inhibition	mg /kg-day	4 x10-3	LEL	0.36	Medium	0210
54	Bayleton	43121-43-3	Decreased body weight gain, erythrocyte count and hemoglobin level	mg /kg-day	3 x10-2	NOEL	2.5	High	0131
55	Baythroid	68359-37-5	Decreased body weights in males, inflammatory foci in kidneys of females	mg /kg-day	2.5 x10-2	NOEL	2.5	High	0132
56	Benefin	1861-40-1	Depressed erythrocyte counts	mg /kg-day	3 x10-1	NOAEL	25	Medium	0133
57	Benomyl	17804-35-2	Decreased pup weanling weights	mg /kg-day	5 x10-2	NOEL	5 mg/kg-day	High	0011
58	Bentazon (Basagran)	25057-89-0	Blood loss into the gastrointestinal tract; coagulation defect in male and female dogs (other effect: Dose-related increase in red areas (presumed blood) in feces; coagulation defect)	mg /kg-day	3.0 x10-2	NOAEL (ADJ)	3.2	Medium	0134
59	Benz[a]anthracene	56-55-3	Not Assessed under the IRIS program						0454
60	Benzaldehyde	100-52-7	Forestomach lesions, kidney toxicity	mg /kg-day	1 x10-1	NOEL	143	Low	0332
61	Benzene	71-43-2	Decreased lymphocyte count	mg /kg-day	4.0 x10-3	BMDL	1.2	Medium	0276
62	Benzidine	92-87-5	Brain cell vacuolization; liver cell alterations in females	mg /kg-day	3 x10-3	LOAEL	2.7	Medium	0135

Inhalation RfCs

Difference between revisions of "IRIS"(mg /m
Obs	Substance	CASRN	Critical Effact(s)	Unit	Inhalation RfC	Type of RfC	Point of Departure(s)*	Overall Confidence	IRIS identifier
1	Acenaphthene	83-32-9	Not Assessed under the IRIS program.
2	Acenaphthylene	208-96-8	Not Assessed under the IRIS program.
3	Acephate	30560-19-1	Not Assessed under the IRIS program.
4	Acetaldehyde	75-07-0	Degeneration of olfactory epithelium	mg /m³	9x10^-3	NOAEL (HEC)	8.7	Low	0290
5	Acetochlor	34256-82-1	Not Assessed under the IRIS program.
6	Acetone	67-64-1	Not Assessed under the IRIS program.
7	Acetonitrile	75-05-8	Not Assessed under the IRIS program.
8	Acetophenone	98-86-2	Mortality	mg /m³	6x10^-2	NOAEL (HEC)	60	Medium	0205
9	Acetyl chloride	75-36-5	Not Assessed under the IRIS program.
10	Acifluorfen, sodium	62476-59-9	Not Assessed under the IRIS program.
11	Acrolein	107-02-8	Nasal lesions	mg /m³	2x10^-5	LOAEL (HEC)	0.02	Medium	0364
12	Acrylamide	79-06-1	Degenerative nerve changes	mg /m³	0.006	HEC (BMDL)	0.18	Medium	0286
13	Acrylic acid	79-10-7	Degeneration of the nasal olfactory epithelium	mg /m³	1x10^-3	LOAEL (HEC)	0.33	Medium	0002
14	Acrylonitrile	107-13-1	Degeneration and inflammation of nasal respiratory epithelium; hyperplasia of mucous secreting cells	mg /m³	2x10^-3	LOAEL (HEC)	1.9	Medium	0206
15	Adiponitrile	111-69-3	Not Assessed under the IRIS program.
16	Alachlor	15972-60-8	Not Assessed under the IRIS program.
17	Alar	1596-84-5	Not Assessed under the IRIS program.
18	Aldicarb	116-06-3	Not Assessed under the IRIS program.
19	Aldicarb sulfone	1646-88-4	Not Assessed under the IRIS program.
20	Aldrin	309-00-2	Not Assessed under the IRIS program.
21	Ally	74223-64-6	Not Assessed under the IRIS program.
22	Allyl alcohol	107-18-6	Not Assessed under the IRIS program.
23	Allyl chloride	107-05-1	Functional and histological peripheral neurotoxicity	mg /m³	1x10^-3	NOAEL (HEC)	3.6	Low	0387
24	Aluminum phosphide	20859-73-8	Not Assessed under the IRIS program.
25	Amdro	67485-29-4	Not Assessed under the IRIS program.
26	Ametryn	834-12-8	Not Assessed under the IRIS program.
27	4-Aminopyridine	504-24-5	Not Assessed under the IRIS program.
28	Amitraz	33089-61-1	Not Assessed under the IRIS program.
29	Ammonia	7664-41-7	Not Assessed under the IRIS program.
30	Ammonium acetate	631-61-8	Not Assessed under the IRIS program.
31	Ammonium methacrylate	16325-47-6	Not Assessed under the IRIS program.
32	Ammonium sulfamate	7773-06-0	Not Assessed under the IRIS program.
33	Aniline	62-53-3	Lack of toxicity (other effect: Mild spleen toxicity )	mg /m³	1x10^-3	NOAEL (HEC)	3.4	Low	0350
34	ortho-Anisidine	90-04-0	Information reviewed but value not estimated. Refer to IRIS Summary.						0610
35	Anthracene	120-12-7	Not Assessed under the IRIS program.
36	Antimony	7440-36-0	Not Assessed under the IRIS program.
37	Antimony trioxide	1309-64-4	Pulmonary toxicity, chronic interstitial inflammation	mg /m³	2x10^-4	BMC₁₀ (HEC)	0.074	Medium	0676
38	Apollo	74115-24-5	Not Assessed under the IRIS program.
39	Aramite	140-57-8	Not Assessed under the IRIS program.
40	Aroclor 1016	12674-11-2	Not Assessed under the IRIS program.
41	Aroclor 1248	12672-29-6	Not Assessed under the IRIS program.
42	Aroclor 1254	11097-69-1	Not Assessed under the IRIS program.
43	Arsenic, inorganic	7440-38-2	Not Assessed under the IRIS program.
44	Arsine	7784-42-1	Increased hemolysis, abnormal RBC morphology, and increased spleen weight (other effect: Increased hemolysis, increased spleen weight, and impaired compensatory erythropoiesis)	mg /m³	5x10^-5	NOAEL (HEC)	0.014	Medium	0672
45	Asbestos	1332-21-4	Not Assessed under the IRIS program.
46	Assure	76578-14-8	Not Assessed under the IRIS program.
47	Asulam	3337-71-1	Not Assessed under the IRIS program.
48	Atrazine	1912-24-9	Not Assessed under the IRIS program.
49	Avermectin B1	65195-55-3	Not Assessed under the IRIS program.
50	Azobenzene	103-33-3	Not Assessed under the IRIS program.
51	Barium and Compounds	7440-39-3	Not Assessed under the IRIS program.
52	Barium cyanide	542-62-1	Not Assessed under the IRIS program.
53	Baygon	114-26-1	Not Assessed under the IRIS program.
54	Bayleton	43121-43-3	Not Assessed under the IRIS program.
55	Baythroid	68359-37-5	Not Assessed under the IRIS program.
56	Benefin	1861-40-1	Not Assessed under the IRIS program.
57	Benomyl	17804-35-2	Not Assessed under the IRIS program.
58	Bentazon (Basagran)	25057-89-0	Not Assessed under the IRIS program.
59	Benz[a]anthracene	56-55-3	Not Assessed under the IRIS program.
60	Benzaldehyde	100-52-7	Not Assessed under the IRIS program.
61	Benzene	71-43-2	Decreased lymphocyte count	mg /m³	3x10^-2	BMCL	8.2	Medium	0276
62	Benzidine	92-87-5	Information reviewed but value not estimated. Refer to IRIS Summary.						0135
63	Benzo[a]pyrene (BaP)	50-32-8	Not Assessed under the IRIS program.
64	Benzo[b]fluoranthene	205-99-2	Not Assessed under the IRIS program.
65	Benzo[g,h,i]perylene	191-24-2	Not Assessed under the IRIS program.
66	Benzo[k]fluoranthene	207-08-9	Not Assessed under the IRIS program.
67	Benzoic acid	65-85-0	Not Assessed under the IRIS program.
68	Benzotrichloride	98-07-7	Not Assessed under the IRIS program.
69	Benzyl chloride	100-44-7	Information reviewed but value not estimated. Refer to IRIS Summary.						0393
70	Beryllium and compounds	7440-41-7	Beryllium sensitization and progression to CBD	mg /m³	2x10^-5	LOAEL (HEC)	0.0002	Medium	0012
71	Bidrin	141-66-2	Not Assessed under the IRIS program.
72	Biphenthrin	82657-04-3	Not Assessed under the IRIS program.
73	1,1-Biphenyl	92-52-4	Information reviewed but value not estimated. Refer to IRIS Summary.						0013
74	Bis(2-chloro-1-methylethyl) ether	108-60-1	Not Assessed under the IRIS program.
75	Bis(2-chloroethoxy)methane	111-91-1	Not Assessed under the IRIS program.
76	Bis(chloroethyl)ether (BCEE)	111-44-4	Information reviewed but value not estimated. Refer to IRIS Summary.						0137
77	Bis(chloromethyl)ether (BCME)	542-88-1	Information reviewed but value not estimated. Refer to IRIS Summary.						0375
78	Bisphenol A.	80-05-7	Not Assessed under the IRIS program.
79	Boron and Compounds	7440-42-8	Information reviewed but value not estimated. Refer to IRIS Summary.						0410
80	Bromate	15541-45-4	Information reviewed but value not estimated. Refer to IRIS Summary.						1002
81	Brominated dibenzofurans	NA	Not Assessed under the IRIS program.
82	Bromobenzene	108-86-1	Hepatocellular cytomegaly in female B6C3F1 mice	mg /m³	6x10^-2	BMCL₁₀ (HEC)	63	Low/Medium	1020
83	Bromochloromethane	74-97-5	Not Assessed under the IRIS program.
84	Bromodichloromethane	75-27-4	Not Assessed under the IRIS program.
85	p-Bromodiphenyl ether	101-55-3	Not Assessed under the IRIS program.
86	Bromoform	75-25-2	Information reviewed but value not estimated. Refer to IRIS Summary.						0214
87	Bromomethane	74-83-9	Degenerative and proliferative lesions of the olfactory epithelium of the nasal cavity	mg /m³	5x10^-3	LOAEL (HEC)	0.48	High	0015
88	Bromotrichloromethane	75-62-7	Not Assessed under the IRIS program.
89	Bromoxynil	1689-84-5	Not Assessed under the IRIS program.
90	Bromoxynil octanoate	1689-99-2	Not Assessed under the IRIS program.
91	1,3-Butadiene	106-99-0	Ovarian atrophy	mg /m³	2x10^-3	BMCL₁₀ (HEC)	1.98	Medium	0139
92	n-Butanol	71-36-3	Not Assessed under the IRIS program.
93	Butyl benzyl phthalate	85-68-7	Not Assessed under the IRIS program.
94	Butylate	2008-41-5	Not Assessed under the IRIS program.
95	t-Butylchloride	507-20-0	Not Assessed under the IRIS program.
96	Butylphthalyl butylglycolate (BPBG)	85-70-1	Not Assessed under the IRIS program.
97	Cacodylic acid	75-60-5	Not Assessed under the IRIS program.
98	Cadmium	7440-43-9	Not Assessed under the IRIS program.
99	Calcium cyanide	592-01-8	Not Assessed under the IRIS program.
100	Caprolactam	105-60-2	Information reviewed but value not estimated. Refer to IRIS Summary.						0357
101	Captafol	2425-06-1	Not Assessed under the IRIS program.
102	Captan	133-06-2	Not Assessed under the IRIS program.
103	Carbaryl	63-25-2	Information reviewed but value not estimated. Refer to IRIS Summary.						0019
104	Carbofuran	1563-66-2	Not Assessed under the IRIS program.
105	Carbon disulfide	75-15-0	Peripheral nervous system dysfunction	mg /m³	7x10^-1	BMC₁₀ (HEC)	19.7	Medium	0217
106	Carbon tetrachloride	56-23-5	Fatty changes in the liver	mg /m³	0.1	BMCL₁₀ (HEC)	14.3	Medium	0020
107	Carbonyl sulfide	463-58-1	Information reviewed but value not estimated. Refer to IRIS Summary.						0617
108	Carbosulfan	55285-14-8	Not Assessed under the IRIS program.
109	Carboxin	5234-68-4	Not Assessed under the IRIS program.
110	Cerium Oxide and Cerium Compounds	1306-38-3	Increased incidence of alveolar epithelial hyperplasia in the lungs of male and female rats	mg /m³	9x10^-4	BMCL (HEC)	0.86	Low	1018
111	Chloral hydrate	302-17-0	Not Assessed under the IRIS program.
112	Chloramben	133-90-4	Not Assessed under the IRIS program.
113	Chlordane (Technical)	12789-03-6	Hepatic effects	mg /m³	7x10^-4	NOAEL (HEC)	0.65	Low	0142
114	Chlordecone (Kepone)	143-50-0	Information reviewed but value not estimated. Refer to IRIS Summary.						1017
115	Chlorimuron-ethyl	90982-32-4	Not Assessed under the IRIS program.
116	Chlorine	7782-50-5	Not Assessed under the IRIS program.
117	Chlorine cyanide	506-77-4	Not Assessed under the IRIS program.
118	Chlorine dioxide	10049-04-4	Vascular congestion and peribronchial edema (other effect: Hemorrhagic alveoli and congested capillaries in the lungs)	mg /m³	2x10^-4	LOAEL (HEC)	0.64	Low	0496
119	Chlorite (sodium salt)	7758-19-2	Information reviewed but value not estimated. Refer to IRIS Summary.						0648
120	1-Chloro-1,1-difluoroethane	75-68-3	No adverse effects	mg /m³	5x10¹	NOAEL (HEC)	14710	Medium	0661
121	2-Chloroacetophenone	532-27-4	Squamous hyperplasia of the nasal respiratory epithelium	mg /m³	3x10^-5	LOAEL (HEC)	0.03	Low	0537
122	p-Chloroaniline	106-47-8	Not Assessed under the IRIS program.
123	Chlorobenzene	108-90-7	Not Assessed under the IRIS program.
124	Chlorobenzilate	510-15-6	Not Assessed under the IRIS program.
125	1-Chlorobutane	109-69-3	Not Assessed under the IRIS program.
126	2-Chlorobutane	78-86-4	Not Assessed under the IRIS program.
127	Chlorocyclopentadiene	41851-50-7	Not Assessed under the IRIS program.
128	Chlorodifluoromethane	75-45-6	Increased kidney, adrenal and pituitary weights (other effect: Reduced maternal weight gain)	mg /m³	5x10¹	NOAEL (HEC)	5260	Medium	0657
129	Chloroform	67-66-3	Not Assessed under the IRIS program.
130	Chloromethyl methyl ether (CMME)	107-30-2	Not Assessed under the IRIS program.
131	beta-Chloronaphthalene	91-58-7	Not Assessed under the IRIS program.
132	2-Chlorophenol	95-57-8	Not Assessed under the IRIS program.
133	p-Chlorophenyl methyl sulfide	123-09-1	Not Assessed under the IRIS program.
134	p-Chlorophenyl methyl sulfone	98-57-7	Not Assessed under the IRIS program.
135	p-Chlorophenyl methyl sulfoxide	934-73-6	Not Assessed under the IRIS program.
136	Chloroprene	126-99-8	Increase in incidence of olfactory atrophy, alveolar hyperplasia, and splenic hematopoietic proliferation in male F344/N rats, female F344/N rats, and female B6C3F1 mice, respectively	mg /m³	2x10^-2	BMDL (HEC)	2	Medium/High	1021
137	Chlorothalonil	1897-45-6	Not Assessed under the IRIS program.
138	o-Chlorotoluene	95-49-8	Not Assessed under the IRIS program.
139	Chlorpropham	101-21-3	Not Assessed under the IRIS program.
140	Chlorpyrifos	2921-88-2	Not Assessed under the IRIS program.
141	Chlorsulfuron	64902-72-3	Not Assessed under the IRIS program.
142	Chromium(III), insoluble salts	16065-83-1	Information reviewed but value not estimated. Refer to IRIS Summary.						0028
143	Chromium(VI) (Chromic acid mists and dissolved Cr(VI) aerosols)	18540-29-9	Nasal septum atrophy	mg /m³	8x10^-6	LOAEL (ADJ)	0.000714	Low	0144
144	Chromium(VI) (Cr(VI) particulates)	18540-29-9	Lactate dehydrogenase in bronchioalveolar lavage fluid		1x10^-4	BMC₁₀ (ADJ)	0.034	Medium	0144
145	Chrysene	218-01-9	Not Assessed under the IRIS program.
146	Coke oven emissions	8007-45-2	Not Assessed under the IRIS program.
147	Copper	7440-50-8	Not Assessed under the IRIS program.
148	Copper cyanide	544-92-3	Not Assessed under the IRIS program.
149	Creosote	8001-58-9	Not Assessed under the IRIS program.
150	Crotonaldehyde	123-73-9	Not Assessed under the IRIS program.
151	Cumene	98-82-8	Increased kidney weights in female rats and adrenal weights in male and female rats	mg /m³	4x10^-1	NOAEL (HEC)	435	Medium	0306
152	Cyanazine	21725-46-2	Not Assessed under the IRIS program.
153	Cyanide, free	57-12-5	Not Assessed under the IRIS program.
154	Cyanogen	460-19-5	Not Assessed under the IRIS program.
155	Cyanogen bromide	506-68-3	Not Assessed under the IRIS program.
156	Cyclohexane	110-82-7	Reduced pup weights in the F1 and F2 generations	mg /m³	6	BMCL_1sd (HEC)	1822	Low/Medium	1005
157	Cyclohexanone	108-94-1	Not Assessed under the IRIS program.
158	Cyclohexylamine	108-91-8	Not Assessed under the IRIS program.
159	Cyhalothrin/Karate	68085-85-8	Not Assessed under the IRIS program.
160	Cypermethrin	52315-07-8	Not Assessed under the IRIS program.
161	Cyromazine	66215-27-8	Not Assessed under the IRIS program.
162	Dacthal	1861-32-1	Not Assessed under the IRIS program.
163	Dalapon, sodium salt	75-99-0	Not Assessed under the IRIS program.
164	Danitol	39515-41-8	Not Assessed under the IRIS program.
165	2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209)	1163-19-5	Information reviewed but value not estimated. Refer to IRIS Summary.						0035
166	Demeton	8065-48-3	Not Assessed under the IRIS program.
167	Di (2-ethylhexyl)phthalate (DEHP)	117-81-7	Not Assessed under the IRIS program.
168	Di(2-ethylhexyl)adipate	103-23-1	Not Assessed under the IRIS program.
169	2,4-Diaminotoluene	95-80-7	Information reviewed but value not estimated. Refer to IRIS Summary.						0536
170	Diazomethane	334-88-3	Information reviewed but value not estimated. Refer to IRIS Summary.						0616
171	Dibenz[a,h]anthracene	53-70-3	Not Assessed under the IRIS program.
172	Dibenzofuran	132-64-9	Not Assessed under the IRIS program.
173	1,2-Dibromo-3-chloropropane (DBCP)	96-12-8	Testicular effects	mg /m³	2x10^-4	NOAEL (HEC)	0.17	Medium	0414
174	1,4-Dibromobenzene	106-37-6	Not Assessed under the IRIS program.
175	Dibromochloromethane	124-48-1	Not Assessed under the IRIS program.
176	Dibromodichloromethane	594-18-3	Not Assessed under the IRIS program.
177	p,p'-Dibromodiphenyl ether	2050-47-7	Not Assessed under the IRIS program.
178	1,2-Dibromoethane	106-93-4	Nasal inflammation	mg /m³	9x10^-3	BMCL₁₀ (HEC)	2.8	Medium	0361
179	Dibutyl phthalate	84-74-2	Information reviewed but value not estimated. Refer to IRIS Summary.						0038
180	Dicamba	1918-00-9	Not Assessed under the IRIS program.
181	Dichloroacetic acid	79-43-6	Information reviewed but value not estimated. Refer to IRIS Summary.						0654
182	1,3-Dichlorobenzene	541-73-1	Not Assessed under the IRIS program.
183	1,4-Dichlorobenzene	106-46-7	Increased liver weights in P1 males	mg /m³	8x10^-1	NOAEL (HEC)	75	Medium	0552
184	1,2-Dichlorobenzene	95-50-1	Not Assessed under the IRIS program.
185	3,3'-Dichlorobenzidine	91-94-1	Information reviewed but value not estimated. Refer to IRIS Summary.						0504
186	Dichlorodifluoromethane	75-71-8	Not Assessed under the IRIS program.
187	p,p'-Dichlorodiphenyl dichloroethane (DDD)	72-54-8	Not Assessed under the IRIS program.
188	p,p'-Dichlorodiphenyldichloroethylene (DDE)	72-55-9	Not Assessed under the IRIS program.
189	p,p'-Dichlorodiphenyltrichloroethane (DDT)	50-29-3	Not Assessed under the IRIS program.
190	1,2-Dichloroethane	107-06-2	Not Assessed under the IRIS program.
191	1,1-Dichloroethane	75-34-3	Not Assessed under the IRIS program.
192	trans-1,2-Dichloroethylene	156-60-5	Information reviewed but value not estimated. Refer to IRIS Summary.						0314
193	cis-1,2-Dichloroethylene	156-59-2	Information reviewed but value not estimated. Refer to IRIS Summary.						0418
194	1,1-Dichloroethylene (1,1-DCE)	75-35-4	Liver toxicity (fatty change)	mg /m³	2x10^-1	BMCL₁₀ (HEC)	6.9	Medium	0039
195	Dichloromethane	75-09-2	Hepatic effects (hepatic vacuolation)	mg /m³	6x10^-1	BMDL₁₀ (HEC)	17.2	Medium/High	0070
196	2,4-Dichlorophenol	120-83-2	Not Assessed under the IRIS program.
197	4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB)	94-82-6	Not Assessed under the IRIS program.
198	2,4-Dichlorophenoxyacetic acid (2,4-D)	94-75-7	Not Assessed under the IRIS program.
199	1,2-Dichloropropane	78-87-5	Hyperplasia of the nasal mucosa	mg /m³	4x10^-3	LOAEL (HEC)	1.3	Medium	0601
200	2,3-Dichloropropanol	616-23-9	Not Assessed under the IRIS program.
201	1,3-Dichloropropene	542-75-6	Hypertrophy/ hyperplasia of the nasal respiratory epithelium	mg /m³	2x10^-2	BMCL₁₀ (HEC)	0.72	High	0224
202	Dichlorvos	62-73-7	Decreased brain cholinesterase activity	mg /m³	5x10^-4	NOAEL (HEC)	0.05	Medium	0151
203	Dicofol	115-32-2	Not Assessed under the IRIS program.
204	Dieldrin	60-57-1	Not Assessed under the IRIS program.
205	Diesel engine exhaust	NA	Pulmonary inflammation and histopathology	mg /m³	5x10^-3	NOAEL (HEC)	0.144	Medium	0642
206	Diethyl phthalate	84-66-2	Not Assessed under the IRIS program.
207	Diethyl sulfate	64-67-5	Information reviewed but value not estimated. Refer to IRIS Summary.						0615
208	Diethyl-p-nitrophenylphosphate	311-45-5	Not Assessed under the IRIS program.
209	Diethylene glycol dinitrate (DEGDN)	693-21-0	Not Assessed under the IRIS program.
210	Difenzoquat	43222-48-6	Not Assessed under the IRIS program.
211	Diflubenzuron	35367-38-5	Not Assessed under the IRIS program.
212	1,1-Difluoroethane	75-37-6	No adverse effects observed	mg /m³	4x10¹	NOAEL (HEC)	12051	Medium	0665
213	Diisopropyl methylphosphonate (DIMP)	1445-75-6	Not Assessed under the IRIS program.
214	Dimethipin	55290-64-7	Not Assessed under the IRIS program.
215	Dimethoate	60-51-5	Not Assessed under the IRIS program.
216	Dimethyl phthalate	131-11-3	Information reviewed but value not estimated. Refer to IRIS Summary.						0353
217	Dimethyl sulfate	77-78-1	Information reviewed but value not estimated. Refer to IRIS Summary.						0365
218	Dimethyl terephthalate (DMT)	120-61-6	Not Assessed under the IRIS program.
219	Dimethylamine	124-40-3	Information reviewed but value not estimated. Refer to IRIS Summary.						0228
220	N-N-Dimethylaniline	121-69-7	Not Assessed under the IRIS program.
221	3,3-Dimethylbenzidine	119-93-7	Information reviewed but value not estimated. Refer to IRIS Summary.						0538
222	N,N-Dimethylformamide	68-12-2	Digestive disturbances and minimal hepatic changes suggestive of liver abnormalities	mg /m³	3x10^-2	LOAEL (HEC)	7.9	Medium	0511
223	3,4-Dimethylphenol	95-65-8	Not Assessed under the IRIS program.
224	2,6-Dimethylphenol	576-26-1	Not Assessed under the IRIS program.
225	2,4-Dimethylphenol	105-67-9	Not Assessed under the IRIS program.
226	4,6-Dinitro-o-cyclohexyl phenol	131-89-5	Not Assessed under the IRIS program.
227	m-Dinitrobenzene	99-65-0	Not Assessed under the IRIS program.
228	o-Dinitrobenzene	528-29-0	Not Assessed under the IRIS program.
229	2,4-Dinitrophenol	51-28-5	Information reviewed but value not estimated. Refer to IRIS Summary.						0152
230	2,4-Dinitrotoluene	121-14-2	Information reviewed but value not estimated. Refer to IRIS Summary.						0542
231	2,4-/2,6-Dinitrotoluene mixture	NA	Not Assessed under the IRIS program.
232	Dinoseb	88-85-7	Not Assessed under the IRIS program.
233	1,4-Dioxane	123-91-1	Information reviewed but value not estimated. Refer to IRIS Summary.						0326
234	Diphenamid	957-51-7	Not Assessed under the IRIS program.
235	Diphenylamine	122-39-4	Not Assessed under the IRIS program.
236	1,2-Diphenylhydrazine	122-66-7	Information reviewed but value not estimated. Refer to IRIS Summary.						0049
237	Diquat	85-00-7	Not Assessed under the IRIS program.
238	Disulfoton	298-04-4	Not Assessed under the IRIS program.
239	1,4-Dithiane	505-29-3	Not Assessed under the IRIS program.
240	Diuron	330-54-1	Not Assessed under the IRIS program.
241	Dodine	2439-10-3	Not Assessed under the IRIS program.
242	Endosulfan	115-29-7	Not Assessed under the IRIS program.
243	Endothall	145-73-3	Not Assessed under the IRIS program.
244	Endrin	72-20-8	Not Assessed under the IRIS program.
245	Epichlorohydrin	106-89-8	Changes in the nasal turbinates	mg /m³	1x10^-3	NOAEL (HEC)	0.36	Medium	0050
246	1,2-Epoxybutane (EBU)	106-88-7	Degenerative lesions of the nasal cavity	mg /m³	2x10^-2	LOAEL (HEC)	4.8	Medium	0630
247	Ethephon	16672-87-0	Not Assessed under the IRIS program.
248	Ethion	563-12-2	Not Assessed under the IRIS program.
249	2-Ethoxyethanol	110-80-5	Decreased testis weight, seminiferous tubule degeneration and decreased hemoglobin	mg /m³	2x10^-1	NOAEL (HEC)	68	Medium	0513
250	Ethyl acetate	141-78-6	Not Assessed under the IRIS program.
251	Ethyl carbamate	51-79-6	Information reviewed but value not estimated. Refer to IRIS Summary.						0629
252	Ethyl chloride	75-00-3	Delayed fetal ossification	mg /m³	1x10^1<7sup>	NOAEL (HEC)	4000	Medium	0523
253	S-Ethyl dipropylthiocarbamate (EPTC)	759-94-4	Not Assessed under the IRIS program.
254	Ethyl ether	60-29-7	Not Assessed under the IRIS program.
255	Ethyl p-nitrophenyl phenylphosphorothioate (EPN)	2104-64-5	Not Assessed under the IRIS program.
256	Ethylbenzene	100-41-4	Developmental toxicity	mg /m³	1	NOAEL (HEC)	434	Low	0051
257	Ethylene diamine	107-15-3	Information reviewed but value not estimated. Refer to IRIS Summary.						0528
258	Ethylene glycol	107-21-1	Not Assessed under the IRIS program.
259	Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol)	111-76-2	Hemosiderin deposition in the liver	mg /m³	1.6	BMCL (HEC)	16	Medium/High	0500
260	Ethylene thiourea (ETU)	96-45-7	Not Assessed under the IRIS program.
261	Ethyleneimine	151-56-4	Information reviewed but value not estimated. Refer to IRIS Summary.						0631
262	Ethylphthalyl ethylglycolate (EPEG)	84-72-0	Not Assessed under the IRIS program.
263	Express	101200-48-0	Not Assessed under the IRIS program.
264	Fenamiphos	22224-92-6	Not Assessed under the IRIS program.
265	Fluometuron	2164-17-2	Not Assessed under the IRIS program.
266	Fluoranthene	206-44-0	Not Assessed under the IRIS program.
267	Fluorene	86-73-7	Not Assessed under the IRIS program.
268	Fluorine (soluble fluoride)	7782-41-4	Not Assessed under the IRIS program.
269	Fluridone	59756-60-4	Not Assessed under the IRIS program.
270	Flurprimidol	56425-91-3	Not Assessed under the IRIS program.
271	Flutolanil	66332-96-5	Not Assessed under the IRIS program.
272	Fluvalinate	69409-94-5	Not Assessed under the IRIS program.
273	Folpet	133-07-3	Not Assessed under the IRIS program.
274	Fomesafen	72178-02-0	Not Assessed under the IRIS program.
275	Fonofos	944-22-9	Not Assessed under the IRIS program.
276	Formaldehyde	50-00-0	Not Assessed under the IRIS program.
277	Formic acid	64-18-6	Not Assessed under the IRIS program.
278	Fosetyl-al	39148-24-8	Not Assessed under the IRIS program.
279	Furan	110-00-9	Not Assessed under the IRIS program.
280	Furfural	98-01-1	Not Assessed under the IRIS program.
281	Furmecyclox	60568-05-0	Not Assessed under the IRIS program.
282	Glufosinate-ammonium	77182-82-2	Not Assessed under the IRIS program.
283	Glycidaldehyde	765-34-4	Not Assessed under the IRIS program.
284	Glyphosate	1071-83-6	Not Assessed under the IRIS program.
285	Haloxyfop-methyl	69806-40-2	Not Assessed under the IRIS program.
286	Harmony	79277-27-3	Not Assessed under the IRIS program.
287	Heptachlor	76-44-8	Not Assessed under the IRIS program.
288	Heptachlor epoxide	1024-57-3	Not Assessed under the IRIS program.
289	n-Heptane	142-82-5	Not Assessed under the IRIS program.
290	Hexabromobenzene	87-82-1	Not Assessed under the IRIS program.
291	Hexabromodiphenyl ether	36483-60-0	Not Assessed under the IRIS program.
292	2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153)	68631-49-2	Information reviewed but value not estimated. Refer to IRIS Summary.						1009
293	Hexachlorobenzene	118-74-1	Information reviewed but value not estimated. Refer to IRIS Summary.						0374
294	Hexachlorobutadiene	87-68-3	Not Assessed under the IRIS program.
295	alpha-Hexachlorocyclohexane (alpha-HCH)	319-84-6	Not Assessed under the IRIS program.
296	beta-Hexachlorocyclohexane (beta-HCH)	319-85-7	Not Assessed under the IRIS program.
297	delta-Hexachlorocyclohexane (delta-HCH)	319-86-8	Not Assessed under the IRIS program.
298	epsilon-Hexachlorocyclohexane (epsilon-HC)	6108-10-7	Not Assessed under the IRIS program.
299	gamma-Hexachlorocyclohexane (gamma-HCH)	58-89-9	Not Assessed under the IRIS program.
300	technical Hexachlorocyclohexane (t-HCH)	608-73-1	Not Assessed under the IRIS program.
301	Hexachlorocyclopentadiene (HCCPD)	77-47-4	Suppurative inflammation of the nose	mg /m³	2x10^-4	NOAEL (HEC)	0.024	Medium	0059
302	Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD	57653-85-7	Not Assessed under the IRIS program.
303	Hexachloroethane	67-72-1	Neurotoxicity (tremors and ruffled pelt)	mg /m³	3x10^-2	NOAEL (HEC)	83	Low	0167
304	Hexachlorophene	70-30-4	Not Assessed under the IRIS program.
305	Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)	121-82-4	Not Assessed under the IRIS program.
306	1,6-Hexamethylene diisocyanate	822-06-0	Degeneration of olfactory epithelium	mg /m³	1x10^-5	NOAEL (HEC)	0.001	Medium	0638
307	n-Hexane	110-54-3	Peripheral neuropathy (decreased MCV at 12 weeks)	mg /m³	7x10^-1	BMCL (HEC)	215	Medium	0486
308	2-Hexanone	591-78-6	Motor conduction velocity of the sciatic-tibial nerve	mg /m³	3x10^-2	BMCL₀₅ (HEC)	90	Low	1019
309	Hexazinone	51235-04-2	Not Assessed under the IRIS program.
310	Hydrazine/Hydrazine sulfate	302-01-2	Not Assessed under the IRIS program.
311	Hydrogen Cyanide and Cyanide Salts	Various	Thyroid enlargement and altered iodide uptake	mg /m³	0.0008	LOAEL (ADJ)	2.5	Low/Medium	0060
312	Hydrogen chloride	7647-01-0	Hyperplasia of nasal mucosa larynx and trachea	mg /m³	2x10^-2	LOAEL (HEC)	6.1	Low	0396
313	Hydrogen sulfide	7783-06-4	Nasal lesions of the olfactory mucosa	mg /m³	2x10^-3	NOAEL (HEC)	0.64	Medium/High	0061
314	Hydroquinone	123-31-9	Information reviewed but value not estimated. Refer to IRIS Summary.
315	Imazalil	35554-44-0	Not Assessed under the IRIS program.
316	Imazaquin	81335-37-7	Not Assessed under the IRIS program.
317	Indeno[1,2,3-cd]pyrene	193-39-5	Not Assessed under the IRIS program.
318	Iprodione	36734-19-7	Not Assessed under the IRIS program.
319	Isobutyl alcohol	78-83-1	Not Assessed under the IRIS program.
320	Isophorone	78-59-1	Information reviewed but value not estimated. Refer to IRIS Summary.
321	Isopropalin	33820-53-0	Not Assessed under the IRIS program.
322	Isopropyl methyl phosphonic acid (IMPA)	1832-54-8	Not Assessed under the IRIS program.
323	Isoxaben	82558-50-7	Not Assessed under the IRIS program.
324	Lactofen	77501-63-4	Not Assessed under the IRIS program.
325	Lead and compounds (inorganic)	7439-92-1	Not Assessed under the IRIS program.
326	d-Limonene	5989-27-5	Information reviewed but value not estimated. Refer to IRIS Summary.
327	Linuron	330-55-2	Not Assessed under the IRIS program.
328	Londax	83055-99-6	Not Assessed under the IRIS program.
329	Malathion	121-75-5	Not Assessed under the IRIS program.
330	Maleic anhydride	108-31-6	Not Assessed under the IRIS program.
331	Maleic hydrazide	123-33-1	Not Assessed under the IRIS program.
332	Maneb	12427-38-2	Not Assessed under the IRIS program.
333	Manganese	7439-96-5	Impairment of neurobehavioral function (other effect: Impairment of neurobehavioral function)	mg /m³	5x10^-5	LOAEL (HEC)	0.05	Medium	0373
334	Mepiquat chloride	24307-26-4	Not Assessed under the IRIS program.
335	Mercuric chloride (HgCl2)	7487-94-7	Not Assessed under the IRIS program.
336	Mercury, elemental	7439-97-6	Hand tremor; increases in memory disturbances; slight subjective and objective evidence of autonomic dysfunction	mg /m³	3x10^-4	LOAEL (ADJ)	0.009	Medium	0370
337	Merphos	150-50-5	Information reviewed but value not estimated. Refer to IRIS Summary.
338	Merphos oxide	78-48-8	Information reviewed but value not estimated. Refer to IRIS Summary.
339	Metalaxyl	57837-19-1	Not Assessed under the IRIS program.
340	Methacrylonitrile	126-98-7	Not Assessed under the IRIS program.
341	Methamidophos	10265-92-6	Not Assessed under the IRIS program.
342	Methanol	67-56-1	Not Assessed under the IRIS program.
343	Methidathion	950-37-8	Not Assessed under the IRIS program.
344	Methomyl	16752-77-5	Not Assessed under the IRIS program.
345	Methoxychlor	72-43-5	Information reviewed but value not estimated. Refer to IRIS Summary.
346	2-Methoxyethanol	109-86-4	Testicular effects	mg /m³	2x10^-2	NOAEL (HEC)	17	Medium	0525
347	Methyl acrylate	96-33-3	Not Assessed under the IRIS program.
348	Methyl chloride	74-87-3	Cerebellar lesions	mg /m³	9x10^-2	NOAEL (HEC)	94.6	Medium	1003
349	Methyl chlorocarbonate	79-22-1	Not Assessed under the IRIS program.
350	Methyl ethyl ketone (MEK)	78-93-3	Developmental toxicity (skeletal variations)	mg /m³	5	LEC (HEC)	1517	Medium	0071
351	Methyl iodide	74-88-4	Not Assessed under the IRIS program.
352	Methyl isobutyl ketone (MIBK)	108-10-1	Reduced fetal body weight, skeletal variations, and increased fetal death in mice, and skeletal variations in rats	mg /m³	3	NOAEL (HEC)	1026	Low/Medium	0173
353	Methyl isocyanate	624-83-9	Information reviewed but value not estimated. Refer to IRIS Summary.
354	Methyl methacrylate	80-62-6	Degeneration/ atrophy of olfactory epithelium (male rats)	mg /m³	7x10^-1	BMC₁₀ (HEC)	7.2	Medium/High	1000
355	Methyl parathion	298-00-0	Not Assessed under the IRIS program.
356	Methyl tert-butyl ether (MTBE)	1634-04-4	Increased absolute and relative liver and kidney weights and increased severity of spontaneous renal lesions (females), increased prostration (females), and swollen periocular tissue (males and females)	mg /m³	3	NOAEL (HEC)	259	Medium	0545
357	4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB)	94-81-5	Not Assessed under the IRIS program.
358	2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP)	93-65-2	Not Assessed under the IRIS program.
359	2-Methyl-4-chlorophenoxyacetic acid (MCPA)	94-74-6	Not Assessed under the IRIS program.
360	Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI)	101-68-8	Hyperplasia of olfactory epithelium	mg /m³	6x10^-4	BMC¹⁰ (HEC)	0.06	Medium	0529
361	4,4'-Methylene bis(N,N'-dimethyl)aniline	101-61-1	Not Assessed under the IRIS program.
362	Methylmercury (MeHg)	22967-92-6	Not Assessed under the IRIS program.
363	2-Methylnaphthalene	91-57-6	Information reviewed but value not estimated. Refer to IRIS Summary.
364	4-Methylphenol	106-44-5	Information reviewed but value not estimated. Refer to IRIS Summary.
365	3-Methylphenol	108-39-4	Information reviewed but value not estimated. Refer to IRIS Summary.
366	2-Methylphenol	95-48-7	Information reviewed but value not estimated. Refer to IRIS Summary.
367	Metolachlor	51218-45-2	Not Assessed under the IRIS program.
368	Metribuzin	21087-64-9	Not Assessed under the IRIS program.
369	Mirex	2385-85-5	Not Assessed under the IRIS program.
370	Molinate	2212-67-1	Not Assessed under the IRIS program.
371	Molybdenum	7439-98-7	Not Assessed under the IRIS program.
372	Monochloramine	10599-90-3	Not Assessed under the IRIS program.
373	Naled	300-76-5	Not Assessed under the IRIS program.
374	Naphthalene	91-20-3	Nasal effects: hyperplasia and metaplasia in respiratory and olfactory epithelium, respectively	mg /m³	3x10^-3	LOAEL (HEC)	9.3	Medium	0436
375	Napropamide	15299-99-7	Not Assessed under the IRIS program.
376	Nickel carbonyl	13463-39-3	Not Assessed under the IRIS program.
377	Nickel refinery dust	NA	Not Assessed under the IRIS program.
378	Nickel subsulfide	12035-72-2	Not Assessed under the IRIS program.
379	Nickel, soluble salts	NA	Not Assessed under the IRIS program.
380	Nitrapyrin	1929-82-4	Not Assessed under the IRIS program.
381	Nitrate	14797-55-8	Not Assessed under the IRIS program.
382	Nitric oxide	10102-43-9	Not Assessed under the IRIS program.
383	Nitrite	14797-65-0	Not Assessed under the IRIS program.
384	Nitrobenzene	98-95-3	Bronchiolization of the alveoli and olfactory degeneration	mg /m³	9x10^-3	BMCL₁₀ (HEC)	0.26	Medium	0079
385	Nitrogen dioxide	10102-44-0	Information reviewed but value not estimated. Refer to IRIS Summary.
386	Nitroguanidine	556-88-7	Not Assessed under the IRIS program.
387	p-Nitrophenol	100-02-7	Information reviewed but value not estimated. Refer to IRIS Summary.
388	2-Nitropropane	79-46-9	Liver focal vacuolization and nodules	mg /m³	2x10^-2	LOAEL (HEC)	16	Low	0519
389	N-Nitroso-N-methylethylamine	10595-95-6	Not Assessed under the IRIS program.
390	N-Nitroso-di-n-butylamine	924-16-3	Not Assessed under the IRIS program.
391	N-Nitrosodi-N-propylamine	621-64-7	Not Assessed under the IRIS program.
392	N-Nitrosodiethanolamine	1116-54-7	Not Assessed under the IRIS program.
393	N-Nitrosodiethylamine	55-18-5	Not Assessed under the IRIS program.
394	N-Nitrosodimethylamine	62-75-9	Not Assessed under the IRIS program.
395	N-Nitrosodiphenylamine	86-30-6	Not Assessed under the IRIS program.
396	N-Nitrosopyrrolidine	930-55-2	Not Assessed under the IRIS program.
397	Nonabromodiphenyl ether	63936-56-1	Not Assessed under the IRIS program.
398	Norflurazon	27314-13-2	Not Assessed under the IRIS program.
399	NuStar	85509-19-9	Not Assessed under the IRIS program.
400	Octabromodiphenyl ether	32536-52-0	Not Assessed under the IRIS program.
401	Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX)	2691-41-0	Not Assessed under the IRIS program.
402	Oryzalin	19044-88-3	Not Assessed under the IRIS program.
403	Oxadiazon	19666-30-9	Not Assessed under the IRIS program.
404	Oxamyl	23135-22-0	Not Assessed under the IRIS program.
405	Oxyfluorfen	42874-03-3	Not Assessed under the IRIS program.
406	Paclobutrazol	76738-62-0	Not Assessed under the IRIS program.
407	Paraquat	1910-42-5	Not Assessed under the IRIS program.
408	Parathion	56-38-2	Not Assessed under the IRIS program.
409	Pendimethalin	40487-42-1	Not Assessed under the IRIS program.
410	Pentabromodiphenyl ether	32534-81-9	Not Assessed under the IRIS program.
411	2,2',4,4',5-Pentabromodiphenyl ether (BDE-99)	60348-60-9	Information reviewed but value not estimated. Refer to IRIS Summary.
412	Pentachlorobenzene	608-93-5	Not Assessed under the IRIS program.
413	Pentachlorocyclopentadiene	25329-35-5	Not Assessed under the IRIS program.
414	Pentachloronitrobenzene (PCNB)	82-68-8	Not Assessed under the IRIS program.
415	Pentachlorophenol	87-86-5	Information reviewed but value not estimated. Refer to IRIS Summary.
416	Pentafluoroethane	354-33-6	Information reviewed but value not estimated. Refer to IRIS Summary.
417	Perchlorate (ClO4) and Perchlorate Salts	7790-98-9	Information reviewed but value not estimated. Refer to IRIS Summary.
418	Permethrin	52645-53-1	Not Assessed under the IRIS program.
419	Phenanthrene	85-01-8	Not Assessed under the IRIS program.
420	Phenmedipham	13684-63-4	Not Assessed under the IRIS program.
421	Phenol	108-95-2	Information reviewed but value not estimated. Refer to IRIS Summary.
422	m-Phenylenediamine	108-45-2	Not Assessed under the IRIS program.
423	Phenylmercuric acetate	62-38-4	Not Assessed under the IRIS program.
424	Phosalone	2310-17-0	Not Assessed under the IRIS program.
425	Phosgene	75-44-5	Collagen staining indicative of fibrosis	mg /m³	3x10^-4	BMDL₁₀ (HEC)	0.03	Medium	0487
426	Phosmet	732-11-6	Not Assessed under the IRIS program.
427	Phosphine	7803-51-2	Decreased body weight	mg /m³	3x10^-4	NOAEL (HEC)	0.25	Low	0090
428	Phosphoric acid	7664-38-2	Bronchiolar fibrosis	mg /m³	1x10^-2	BMC₁₀ (HEC)	3.4	Medium	0697
429	Phthalic anhydride	85-44-9	Not Assessed under the IRIS program.
430	Picloram	1918-02-1	Not Assessed under the IRIS program.
431	Pirimiphos-methyl	29232-93-7	Not Assessed under the IRIS program.
432	Polychlorinated biphenyls (PCBs)	1336-36-3	Not Assessed under the IRIS program.
433	Potassium cyanide	151-50-8	Not Assessed under the IRIS program.
434	Potassium silver cyanide	506-61-6	Not Assessed under the IRIS program.
435	Prochloraz	67747-09-5	Not Assessed under the IRIS program.
436	Prometon	1610-18-0	Not Assessed under the IRIS program.
437	Prometryn	7287-19-6	Not Assessed under the IRIS program.
438	Pronamide	23950-58-5	Not Assessed under the IRIS program.
439	Propachlor	1918-16-7	Not Assessed under the IRIS program.
440	Propanil	709-98-8	Not Assessed under the IRIS program.
441	Propargite	2312-35-8	Not Assessed under the IRIS program.
442	Propargyl alcohol	107-19-7	Not Assessed under the IRIS program.
443	Propazine	139-40-2	Not Assessed under the IRIS program.
444	Propham	122-42-9	Not Assessed under the IRIS program.
445	Propiconazole	60207-90-1	Not Assessed under the IRIS program.
446	beta-Propiolactone	57-57-8	Information reviewed but value not estimated. Refer to IRIS Summary.
447	Propionaldehyde	123-38-6	Atrophy of olfactory epithelium	mg /m³	8x10^-3	BMCL₁₀ (HEC)	8	Low/Medium	1011
448	Propylene glycol	57-55-6	Information reviewed but value not estimated. Refer to IRIS Summary.
449	Propylene glycol monoethyl ether	52125-53-8	Information reviewed but value not estimated. Refer to IRIS Summary.
450	Propylene glycol monomethyl ether (PGME)	107-98-2	Mild reversible sedation	mg /m³	2	NOAEL (HEC)	658	Medium	0404
451	Propylene oxide	75-56-9	Nest-like infolds of the nasal respiratory epithelium	mg /m³	3x10^-2	LOAEL (HEC)	2.9	Medium	0403
452	Propyleneimine	75-55-8	Information reviewed but value not estimated. Refer to IRIS Summary.
453	Pursuit	81335-77-5	Not Assessed under the IRIS program.
454	Pydrin	51630-58-1	Not Assessed under the IRIS program.
455	Pyrene	129-00-0	Not Assessed under the IRIS program.
456	Pyridine	110-86-1	Not Assessed under the IRIS program.
457	Quinalphos	13593-03-8	Not Assessed under the IRIS program.
458	Quinoline	91-22-5	Information reviewed but value not estimated. Refer to IRIS Summary.
459	Quinone	106-51-4	Information reviewed but value not estimated. Refer to IRIS Summary.
460	Radium 226,228	7440-14-4	Not Assessed under the IRIS program.
461	Radon 222	14859-67-7	Not Assessed under the IRIS program.
462	Refractory ceramic fibers	NA	Not Assessed under the IRIS program.
463	Resmethrin	10453-86-8	Not Assessed under the IRIS program.
464	Rotenone	83-79-4	Not Assessed under the IRIS program.
465	Savey	78587-05-0	Not Assessed under the IRIS program.
466	Selenious acid	7783-00-8	Not Assessed under the IRIS program.
467	Selenium and Compounds	7782-49-2	Not Assessed under the IRIS program.
468	Selenium sulfide	7446-34-6	Not Assessed under the IRIS program.
469	Selenourea	630-10-4	Not Assessed under the IRIS program.
470	Sethoxydim	74051-80-2	Not Assessed under the IRIS program.
471	Silver	7440-22-4	Not Assessed under the IRIS program.
472	Silver cyanide	506-64-9	Not Assessed under the IRIS program.
473	Simazine	122-34-9	Not Assessed under the IRIS program.
474	Sodium azide	26628-22-8	Not Assessed under the IRIS program.
475	Sodium cyanide	143-33-9	Not Assessed under the IRIS program.
476	Sodium diethyldithiocarbamate	148-18-5	Not Assessed under the IRIS program.
477	Sodium fluoroacetate	62-74-8	Not Assessed under the IRIS program.
478	Strontium	7440-24-6	Not Assessed under the IRIS program.
479	Strychnine	57-24-9	Not Assessed under the IRIS program.
480	Styrene	100-42-5	CNS effects	mg /m³	1	NOAEL (HEC)	34	Medium	0104
481	Systhane	88671-89-0	Not Assessed under the IRIS program.
482	Tebuthiuron	34014-18-1	Not Assessed under the IRIS program.
483	Terbacil	5902-51-2	Not Assessed under the IRIS program.
484	Terbutryn	886-50-0	Not Assessed under the IRIS program.
485	Tetrabromodiphenyl ether	40088-47-9	Not Assessed under the IRIS program.
486	2,2',4,4'-Tetrabromodiphenyl ether (BDE-47)	5436-43-1	Information reviewed but value not estimated. Refer to IRIS Summary.
487	1,2,4,5-Tetrachlorobenzene	95-94-3	Not Assessed under the IRIS program.
488	Tetrachlorocyclopentadiene	695-77-2	Not Assessed under the IRIS program.
489	2,3,7,8-Tetrachlorodibenzo-p-dioxin	1746-01-6	Not Assessed under the IRIS program.
490	1,1,1,2-Tetrachloroethane	630-20-6	Not Assessed under the IRIS program.
491	1,1,2,2-Tetrachloroethane	79-34-5	Information reviewed but value not estimated. Refer to IRIS Summary.
492	Tetrachloroethylene	127-18-4	Not Assessed under the IRIS program.
493	2,3,4,6-Tetrachlorophenol	58-90-2	Not Assessed under the IRIS program.
494	Tetrachlorovinphos	961-11-5	Not Assessed under the IRIS program.
495	Tetraethyl lead	78-00-2	Not Assessed under the IRIS program.
496	Tetraethyldithiopyrophosphate	3689-24-5	Not Assessed under the IRIS program.
497	1,1,1,2-Tetrafluoroethane	811-97-2	Leydig cell hyperplasia	mg /m³	8x10¹	BMC₁₀ (HEC)	8200	Medium	0656
498	Thallium (I), soluble salts	Various	Information reviewed but value not estimated. Refer to IRIS Summary.
499	Thallium acetate	563-68-8	Information reviewed but value not estimated. Refer to IRIS Summary.
500	Thallium carbonate	6533-73-9	Information reviewed but value not estimated. Refer to IRIS Summary.
501	Thallium chloride	7791-12-0	Information reviewed but value not estimated. Refer to IRIS Summary.
502	Thallium nitrate	10102-45-1	Information reviewed but value not estimated. Refer to IRIS Summary.
503	Thallium oxide	1314-32-5	Information reviewed but value not estimated. Refer to IRIS Summary.
504	Thallium selenite	12039-52-0	Information reviewed but value not estimated. Refer to IRIS Summary.
505	Thallium(I) sulfate	7446-18-6	Information reviewed but value not estimated. Refer to IRIS Summary.
506	Thiobencarb	28249-77-6	Not Assessed under the IRIS program.
507	Thiophanate-methyl	23564-05-8	Not Assessed under the IRIS program.
508	Thiram	137-26-8	Not Assessed under the IRIS program.
509	Toluene	108-88-3	Neurological effects in occupationally-exposed workers (other effect:)	mg /m³	5	NOAEL (ADJ)	46	High	0118
510	2,4-/2,6-Toluene diisocyanate mixture (TDI)	26471-62-5	Chronic lung-function decline	mg /m³	7x10^-5	NOAEL (HEC)	0.002	Medium	0503
511	Toxaphene	8001-35-2	Not Assessed under the IRIS program.
512	Tralomethrin	66841-25-6	Not Assessed under the IRIS program.
513	Triallate	2303-17-5	Not Assessed under the IRIS program.
514	Triasulfuron	82097-50-5	Not Assessed under the IRIS program.
515	1,2,4-Tribromobenzene	615-54-3	Not Assessed under the IRIS program.
516	Tribromochloromethane	594-15-0	Not Assessed under the IRIS program.
517	Tribromodiphenyl ether	49690-94-0	Not Assessed under the IRIS program.
518	Tributyltin oxide (TBTO)	56-35-9	Information reviewed but value not estimated. Refer to IRIS Summary.
519	1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113)	76-13-1	Not Assessed under the IRIS program.
520	Trichloroacetic acid	76-03-9	Information reviewed but value not estimated. Refer to IRIS Summary.
521	1,2,4-Trichlorobenzene	120-82-1	Not Assessed under the IRIS program.
522	Trichlorocyclopentadiene	77323-84-3	Not Assessed under the IRIS program.
523	1,1,2-Trichloroethane	79-00-5	Not Assessed under the IRIS program.
524	1,1,1-Trichloroethane	71-55-6	Liver histopathologic changes	mg /m³	5	NOEL (HEC)	1553	Medium	0197
525	Trichloroethylene	79-01-6	Decreased thymus weight in female B6C3F1 mice (immunotoxicity)	mg /m³	0.002	LOAEL (HEC₉₉)	0.19	High	0199
526	Trichloroethylene	79-01-6	Increased fetal cardiac malformations in Sprague-Dawley rats (heart malformations)	mg /m³	0.002	BMDL₀₁ (HEC₉₉)	0.021	High	0199
527	Trichlorofluoromethane	75-69-4	Not Assessed under the IRIS program.
528	2,4,5-Trichlorophenol	95-95-4	Information reviewed but value not estimated. Refer to IRIS Summary.
529	2,4,6-Trichlorophenol	88-06-2	Information reviewed but value not estimated. Refer to IRIS Summary.
530	2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP)	93-72-1	Not Assessed under the IRIS program.
531	2,4,5-Trichlorophenoxyacetic acid (2,4,5-T)	93-76-5	Not Assessed under the IRIS program.
532	1,1,2-Trichloropropane	598-77-6	Not Assessed under the IRIS program.
533	1,2,3-Trichloropropane	96-18-4	peribronchial lymphoid hyperplasia in male rats	mg /m³	0.0003	BMCL (HEC)	0.90	Low	0200
534	Tricresol	1319-77-3	Information reviewed but value not estimated. Refer to IRIS Summary.
535	Tridiphane	58138-08-2	Not Assessed under the IRIS program.
536	Triethylamine	121-44-8	No observed adverse effects (other effect: Inflammation of the nasal passage)	mg /m³	7x10^-3	NOAEL (HEC)	19.5	Low	0520
537	Triethylene glycol monobutyl ether	143-22-6	Information reviewed but value not estimated. Refer to IRIS Summary.
538	Triethylene glycol monoethyl ether	112-50-5	Information reviewed but value not estimated. Refer to IRIS Summary.
539	Trifluralin	1582-09-8	Not Assessed under the IRIS program.
540	2,2,4-Trimethylpentane	540-84-1	Information reviewed but value not estimated. Refer to IRIS Summary.
541	1,3,5-Trinitrobenzene	99-35-4	Not Assessed under the IRIS program.
542	2,4,6-Trinitrotoluene (TNT)	118-96-7	Not Assessed under the IRIS program.
543	Uranium, natural	7440-61-1	Not Assessed under the IRIS program.
544	Uranium, soluble salts	NA	Not Assessed under the IRIS program.
545	Urea	57-13-6	Information reviewed but value not estimated. Refer to IRIS Summary.
546	Vanadium pentoxide	1314-62-1	Not Assessed under the IRIS program.
547	Vernam	1929-77-7	Not Assessed under the IRIS program.
548	Vinclozolin	50471-44-8	Not Assessed under the IRIS program.
549	Vinyl acetate	108-05-4	Nasal epithelial lesions	mg /m³	2x10^-1	NOAEL (HEC)	5	High	0512
550	Vinyl bromide	593-60-2	Hypertrophy, basophilic and eosinophilic foci, in the liver	mg /m³	3x10^-3	LOAEL (HEC)	7.7	Low	0671
551	Vinyl chloride	75-01-4	Liver cell polymorphism	mg /m³	1x10^-1	NOAEL (HEC)	2.5	Medium	1001
552	Warfarin	81-81-2	Not Assessed under the IRIS program.
553	White phosphorus	7723-14-0	Not Assessed under the IRIS program.
554	Xylenes	1330-20-7	Impaired motor coordination (decreased rotarod performance)	mg /m³	0.1	NOAEL (HEC)	39	Medium	0270
555	Zinc and Compounds	7440-66-6	Not Assessed under the IRIS program.
556	Zinc cyanide	557-21-1	Not Assessed under the IRIS program.
557	Zinc phosphide	1314-84-7	Not Assessed under the IRIS program.
558	Zineb	12122-67-7	Not Assessed under the IRIS program.

Inhalation unit risks

Difference between revisions of "IRIS"(per µg /m
Obs	Substance	CASRN	Precursor Effect/ Tumor Type	Extrapolation Method	Unit	Inhalation unit risks	Study Route
1	Acenaphthene	83-32-9	Not Assessed under the IRIS program.
2	Acenaphthylene	208-96-8	Not Assessed under the IRIS program.
3	Acephate	30560-19-1	Not Assessed under the IRIS program.
4	Acetaldehyde	75-07-0	Nasal squamous cell carcinoma or adenocarcinoma	Linearized multistage-variable exposure input form (extra risk)	per µg/m³	2.2x10^-6	Inhalation
5	Acetochlor	34256-82-1	Not Assessed under the IRIS program.
6	Acetone	67-64-1	Not Assessed under the IRIS program.
7	Acetonitrile	75-05-8	Not Assessed under the IRIS program.
8	Acetophenone	98-86-2	Not Assessed under the IRIS program.
9	Acetyl chloride	75-36-5	Not Assessed under the IRIS program.
10	Acifluorfen, sodium	62476-59-9	Not Assessed under the IRIS program.
11	Acrolein	107-02-8	Not Assessed under the IRIS program.
12	Acrylamide	79-06-1	thyroid tumors and tunica vaginalis mesotheliomas	Multistage model with linear extrapolation from the point of departure (BMDL), summed risk.	per µg /m³	1x10^-4	Oral, drinking water
13	Acrylic acid	79-10-7	Not Assessed under the IRIS program.
14	Acrylonitrile	107-13-1	Respiratory cancer	Average relative risk	per µg /m³	6.8x10^-5	Inhalation
15	Adiponitrile	111-69-3	Not Assessed under the IRIS program.
16	Alachlor	15972-60-8	Not Assessed under the IRIS program.
17	Alar	1596-84-5	Not Assessed under the IRIS program.
18	Aldicarb	116-06-3	Not Assessed under the IRIS program.
19	Aldicarb sulfone	1646-88-4	Not Assessed under the IRIS program.
20	Aldrin	309-00-2	Liver carcinoma	Linearized multistage procedure, extra risk	per µg /m³	4.9x10^-3	Oral, Diet
21	Ally	74223-64-6	Not Assessed under the IRIS program.
22	Allyl alcohol	107-18-6	Not Assessed under the IRIS program.
23	Allyl chloride	107-05-1	Not Assessed under the IRIS program.
24	Aluminum phosphide	20859-73-8	Not Assessed under the IRIS program.
25	Amdro	67485-29-4	Not Assessed under the IRIS program.
26	Ametryn	834-12-8	Not Assessed under the IRIS program.
27	4-Aminopyridine	504-24-5	Not Assessed under the IRIS program.
28	Amitraz	33089-61-1	Not Assessed under the IRIS program.
29	Ammonia	7664-41-7	Not Assessed under the IRIS program.
30	Ammonium acetate	631-61-8	Not Assessed under the IRIS program.
31	Ammonium methacrylate	16325-47-6	Not Assessed under the IRIS program.
32	Ammonium sulfamate	7773-06-0	Not Assessed under the IRIS program.
33	Aniline	62-53-3	Not Assessed under the IRIS program.
34	ortho-Anisidine	90-04-0	Not Assessed under the IRIS program.
35	Anthracene	120-12-7	Not Assessed under the IRIS program.
36	Antimony	7440-36-0	Not Assessed under the IRIS program.
37	Antimony trioxide	1309-64-4	Not Assessed under the IRIS program.
38	Apollo	74115-24-5	Not Assessed under the IRIS program.
39	Aramite	140-57-8	Neoplastic liver nodules and carcinomas	Linearized multistage procedure, extra risk	per µg/m³	7.1x10^-6	Oral, Diet
40	Aroclor 1016	12674-11-2	Not Assessed under the IRIS program.
41	Aroclor 1248	12672-29-6	Not Assessed under the IRIS program.
42	Aroclor 1254	11097-69-1	Not Assessed under the IRIS program.
43	Arsenic, inorganic	7440-38-2	Lung cancer	Absolute-risk linear model	per µg/m³	4.3x10^-3	Inhalation, Occupational exposure
44	Arsine	7784-42-1	Not Assessed under the IRIS program.
45	Asbestos	1332-21-4	Lung cancer and mesothelioma	Additive risk of lung cancer and mesothelioma, using relative risk model for lung cancer and absolute risk model for mesothelioma	per f/mL	2.3x10^-1	Inhalation, Occupational exposure
46	Assure	76578-14-8	Not Assessed under the IRIS program.
47	Asulam	3337-71-1	Not Assessed under the IRIS program.
48	Atrazine	1912-24-9	Not Assessed under the IRIS program.
49	Avermectin B1	65195-55-3	Not Assessed under the IRIS program.
50	Azobenzene	103-33-3	Abdominal cavity sarcomas	Linearized multistage procedure, extra risk	per µg /m³	3.1x10^-5	Oral, Diet
51	Barium and Compounds	7440-39-3	Not Assessed under the IRIS program.
52	Barium cyanide	542-62-1	Not Assessed under the IRIS program.
53	Baygon	114-26-1	Not Assessed under the IRIS program.
54	Bayleton	43121-43-3	Not Assessed under the IRIS program.
55	Baythroid	68359-37-5	Not Assessed under the IRIS program.
56	Benefin	1861-40-1	Not Assessed under the IRIS program.
57	Benomyl	17804-35-2	Not Assessed under the IRIS program.
58	Bentazon (Basagran)	25057-89-0	Not Assessed under the IRIS program.
59	Benz[a]anthracene	56-55-3	Not Assessed under the IRIS program.
60	Benzaldehyde	100-52-7	Not Assessed under the IRIS program.
61	Benzene	71-43-2	Leukemia	Low-dose linearity utilizing maximum likelihood estimates	per µg /m³	2.2x10^-6	Inhalation
62	Benzene	71-43-2	Leukemia	Low-dose linearity utilizing maximum likelihood estimates	per µg /m³	7.8x10^-6	Inhalation
63	Benzidine	92-87-5	Bladder tumors	One-hit with time factor, extra risk	per µg /m³	6.7x10^-2	Inhalation, Occupational exposure
64	Benzo[a]pyrene (BaP)	50-32-8	Not Assessed under the IRIS program.
65	Benzo[b]fluoranthene	205-99-2	Not Assessed under the IRIS program.
66	Benzo[g,h,i]perylene	191-24-2	Not Assessed under the IRIS program.
67	Benzo[k]fluoranthene	207-08-9	Not Assessed under the IRIS program.
68	Benzoic acid	65-85-0	Not Assessed under the IRIS program.
69	Benzotrichloride	98-07-7	Not Assessed under the IRIS program.
70	Benzyl chloride	100-44-7	Not Assessed under the IRIS program.
71	Beryllium and compounds	7440-41-7	Lung cancer	Relative risk	per µg /m³	2.4x10^-3	Inhalation, Occupational exposure
72	Bidrin	141-66-2	Not Assessed under the IRIS program.
73	Biphenthrin	82657-04-3	Not Assessed under the IRIS program.
74	1,1-Biphenyl	92-52-4	Not Assessed under the IRIS program.
75	Bis(2-chloro-1-methylethyl) ether	108-60-1	Not Assessed under the IRIS program.
76	Bis(2-chloroethoxy)methane	111-91-1	Not Assessed under the IRIS program.
77	Bis(chloroethyl)ether (BCEE)	111-44-4	Hepatomas	Linearized multistage procedure, extra risk	per µg /m³	3.3x10^-4	Oral, Gavage followed by diet
78	Bis(chloromethyl)ether (BCME)	542-88-1	Respiratory tract tumors	Linearized multistage procedure, extra risk	per µg /m³	6.2x10^-2	Inhalation
79	Bisphenol A.	80-05-7	Not Assessed under the IRIS program.
80	Boron and Compounds	7440-42-8	Not Assessed under the IRIS program.
81	Bromate	15541-45-4	Information reviewed but value not estimated. Refer to IRIS Summary.
82	Brominated dibenzofurans	NA	Not Assessed under the IRIS program.
83	Bromobenzene	108-86-1	Not Assessed under the IRIS program.
84	Bromochloromethane	74-97-5	Not Assessed under the IRIS program.
85	Bromodichloromethane	75-27-4	Not Assessed under the IRIS program.
86	p-Bromodiphenyl ether	101-55-3	Not Assessed under the IRIS program.
87	Bromoform	75-25-2	Neoplastic lesions in the large intestine	Linearized multistage procedure, extra risk	per µg /m³	1.1x10^-6	Oral, Gavage in corn oil
88	Bromomethane	74-83-9	Not Assessed under the IRIS program.
89	Bromotrichloromethane	75-62-7	Not Assessed under the IRIS program.
90	Bromoxynil	1689-84-5	Not Assessed under the IRIS program.
91	Bromoxynil octanoate	1689-99-2	Not Assessed under the IRIS program.
92	1,3-Butadiene	106-99-0	Leukemia	Linear extrapolation from LEC01 (0.254 ppm); LEC01 derived from linear relative rate model (RR = 1 + (B)(x)) using lifetable analysis with leukemia incidence data; an adjustment factor of 2 was applied.	per µg /m³	3x10^-5	Inhalation
93	n-Butanol	71-36-3	Not Assessed under the IRIS program.
94	Butyl benzyl phthalate	85-68-7	Not Assessed under the IRIS program.
95	Butylate	2008-41-5	Not Assessed under the IRIS program.
96	t-Butylchloride	507-20-0	Not Assessed under the IRIS program.
97	Butylphthalyl butylglycolate (BPBG)	85-70-1	Not Assessed under the IRIS program.
98	Cacodylic acid	75-60-5	Not Assessed under the IRIS program.
99	Cadmium	7440-43-9	Lung, trachea, bronchus cancer deaths	Two stage; only first affected by exposure; extra risk	per µg /m³	1.8x10^-3	Inhalation, Exposure in the workplace
100	Calcium cyanide	592-01-8	Not Assessed under the IRIS program.
101	Caprolactam	105-60-2	Not Assessed under the IRIS program.
102	Captafol	2425-06-1	Not Assessed under the IRIS program.
103	Captan	133-06-2	Not Assessed under the IRIS program.
104	Carbary	l63-25-2	Not Assessed under the IRIS program.
105	Carbofuran1	563-66-2	Not Assessed under the IRIS program.
106	Carbon disulfide	75-15-0	Not Assessed under the IRIS program.
107	Carbon tetrachloride	56-23-5	Pheochromocytoma	Log-probit model with linear extrapolation from the POD (LEC10).	per µg /m³	6x10^-6	Inhalation
108	Carbonyl sulfide	463-58-1	Not Assessed under the IRIS program.
109	Carbosulfan	55285-14-8	Not Assessed under the IRIS program.
110	Carboxin	5234-68-4	Not Assessed under the IRIS program.
111	Cerium Oxide and Cerium Compounds	1306-38-3	Not Assessed under the IRIS program.
112	Chloral hydrate	302-17-0	Not Assessed under the IRIS program.
113	Chloramben	133-90-4	Not Assessed under the IRIS program.
114	Chlordane (Technical)	12789-03-6	Hepatocellular carcinoma	Linearized multistage procedure, extra risk	per µg /m³	1x10^-4<7sup>	Oral, Diet
115	Chlordecone (Kepone)	143-50-0	Information reviewed but value not estimated. Refer to IRIS Summary.
116	Chlorimuron-ethyl	90982-32-4	Not Assessed under the IRIS program.
117	Chlorine	7782-50-5	Not Assessed under the IRIS program.
118	Chlorine cyanide	506-77-4	Not Assessed under the IRIS program.
119	Chlorine dioxide	10049-04-4	Not Assessed under the IRIS program.
120	Chlorite (sodium salt)	7758-19-2	Not Assessed under the IRIS program.
121	1-Chloro-1,1-difluoroethane	75-68-3	Not Assessed under the IRIS program.
122	2-Chloroacetophenone	532-27-4	Not Assessed under the IRIS program.
123	p-Chloroaniline	106-47-8	Not Assessed under the IRIS program.
124	Chlorobenzene	108-90-7	Not Assessed under the IRIS program.
125	Chlorobenzilate	510-15-6	Not Assessed under the IRIS program.
126	1-Chlorobutane	109-69-3	Not Assessed under the IRIS program.
127	2-Chlorobutane	78-86-4	Not Assessed under the IRIS program.
128	Chlorocyclopentadiene	41851-50-7	Not Assessed under the IRIS program.
129	Chlorodifluoromethane	75-45-6	Not Assessed under the IRIS program.
130	Chloroform	67-66-3	Hepatocellular carcinoma	Linearized multistage procedure, extra risk	per µg /m³	2.3x10^-5	Oral, Gavage
131	Chloromethyl methyl ether (CMME)	107-30-2	Not Assessed under the IRIS program.
132	beta-Chloronaphthalene	91-58-7	Not Assessed under the IRIS program.
133	2-Chlorophenol	95-57-8	Not Assessed under the IRIS program.
134	p-Chlorophenyl methyl sulfide	123-09-1	Not Assessed under the IRIS program.
135	p-Chlorophenyl methyl sulfone	98-57-7	Not Assessed under the IRIS program.
136	p-Chlorophenyl methyl sulfoxide	934-73-6	Not Assessed under the IRIS program.
137	Chloroprene	126-99-8	alveolar/ bronchiolar adenoma or carcinoma; hemangioma/ hemangiosarcoma (all organs); mammary gland adenocarcinoma, carcinoma, or adenoacanthoma; forestomach squamous cell papilloma or carcinoma; hepatocellular adenoma or carcinoma; Harderian gland adenoma or carcinoma; skin sarcoma; and Zymbal's gland carcinoma	Multistage model with linear extrapolation from the point of departure (BMDL), summed risk.	per µg /m³	3x10^-4	Inhalation
138	Chlorothalonil	1897-45-6	Not Assessed under the IRIS program.
139	o-Chlorotoluene	95-49-8	Not Assessed under the IRIS program.
140	Chlorpropham	101-21-3	Not Assessed under the IRIS program.
141	Chlorpyrifos	2921-88-2	Not Assessed under the IRIS program.
142	Chlorsulfuron	64902-72-3	Not Assessed under the IRIS program.
143	Chromium(III), insoluble salts	16065-83-1	Not Assessed under the IRIS program.
144	Chromium(VI)	18540-29-9	Lung cancer	Multistage, extra risk	per µg /m³	1.2x10^-2	Inhalation, Occupational exposure
145	Chrysene	218-01-9	Not Assessed under the IRIS program.
146	Coke oven emissions	8007-45-2	Respiratory cancer	Linearized multistage procedure	per µg /m³	6.2x10^-4	Inhalation, Occupational
147	Copper	7440-50-8	Not Assessed under the IRIS program.
148	Copper cyanide	544-92-3	Not Assessed under the IRIS program.
149	Creosote	8001-58-9	Not Assessed under the IRIS program.
150	Crotonaldehyde	123-73-9	Not Assessed under the IRIS program.
151	Cumene	98-82-8	Not Assessed under the IRIS program.
152	Cyanazine	21725-46-2	Not Assessed under the IRIS program.
153	Cyanide, free	57-12-5	Not Assessed under the IRIS program.
154	Cyanogen	460-19-5	Not Assessed under the IRIS program.
155	Cyanogen bromide	506-68-3	Not Assessed under the IRIS program.
156	Cyclohexane	110-82-7	Not Assessed under the IRIS program.
157	Cyclohexanone	108-94-1	Not Assessed under the IRIS program.
158	Cyclohexylamine	108-91-8	Not Assessed under the IRIS program.
159	Cyhalothrin/Karate	68085-85-8	Not Assessed under the IRIS program.
160	Cypermethrin	52315-07-8	Not Assessed under the IRIS program.
161	Cyromazine	66215-27-8	Not Assessed under the IRIS program.
162	Dacthal	1861-32-1	Not Assessed under the IRIS program.
163	Dalapon, sodium salt	75-99-0	Not Assessed under the IRIS program.
164	Danitol	39515-41-8	Not Assessed under the IRIS program.
165	2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209)	1163-19-5	Not Assessed under the IRIS program.
166	Demeton	8065-48-3	Not Assessed under the IRIS program.
167	Di (2-ethylhexyl)phthalate (DEHP)	117-81-7	Not Assessed under the IRIS program.
168	Di(2-ethylhexyl)adipate	103-23-1	Not Assessed under the IRIS program.
169	2,4-Diaminotoluene	95-80-7	Not Assessed under the IRIS program.
170	Diazomethane	334-88-3	Not Assessed under the IRIS program.
171	Dibenz[a,h]anthracene	53-70-3	Not Assessed under the IRIS program.
172	Dibenzofuran	132-64-9	Not Assessed under the IRIS program.
173	1,2-Dibromo-3-chloropropane (DBCP)	96-12-8	Not Assessed under the IRIS program.
174	1,4-Dibromobenzene	106-37-6	Not Assessed under the IRIS program.
175	Dibromochloromethane	124-48-1	Not Assessed under the IRIS program.
176	Dibromodichloromethane	594-18-3	Not Assessed under the IRIS program.
177	p,p'-Dibromodiphenyl ether	2050-47-7	Not Assessed under the IRIS program.
178	1,2-Dibromoethane	106-93-4	Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas	Multistage-Weibull model; linear extrapolation from lower 95% confidence limit on dose associated with extra risk (adjusted for background) at point of departure at lower end of data range.	per µg /m³	6x10^-4	Inhalation
179	1,2-Dibromoethane	106-93-4	Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas	Multistage-Weibull model; linear extrapolation from lower 95% confidence limit on dose associated with extra risk (adjusted for background) at point of departure at lower end of data range.	per µg /m³	3x10^-4	Inhalation
180	Dibutyl phthalate	84-74-2	Not Assessed under the IRIS program.
181	Dicamba	1918-00-9	Not Assessed under the IRIS program.
182	Dichloroacetic acid	79-43-6	Information reviewed but value not estimated. Refer to IRIS Summary.
183	1,3-Dichlorobenzene	541-73-1	Not Assessed under the IRIS program.
184	1,4-Dichlorobenzene	106-46-7	Not Assessed under the IRIS program.
185	1,2-Dichlorobenzene	95-50-1	Not Assessed under the IRIS program.
186	3,3'-Dichlorobenzidine	91-94-1	Not Assessed under the IRIS program.
187	Dichlorodifluoromethane	75-71-8	Not Assessed under the IRIS program.
188	p,p'-Dichlorodiphenyl dichloroethane (DDD)	72-54-8	Not Assessed under the IRIS program.
189	p,p'-Dichlorodiphenyldichloroethylene (DDE)	72-55-9	Not Assessed under the IRIS program.
190	p,p'-Dichlorodiphenyltrichloroethane (DDT)	50-29-3	Liver tumors, benign and malignant	Linear multistage procedure, extra risk	per µg /m³	9.7x10^-5	Oral,Diet
191	1,2-Dichloroethane	107-06-2	Hemangiosarcomas	Linearized multistage procedure, extra risk	per µg /m³	2.6x10^-5	Oral,Gavage
192	1,1-Dichloroethane	75-34-3	Not Assessed under the IRIS program.
193	trans-1,2-Dichloroethylene	156-60-5	Not Assessed under the IRIS program.
194	cis-1,2-Dichloroethylene	156-59-2	Not Assessed under the IRIS program.
195	1,1-Dichloroethylene (1,1-DCE)	75-35-4	Information reviewed but value not estimated. Refer to IRIS Summary.
196	Dichloromethane	75-09-2	Hepatocellular carcinomas or adenomas, bronchoalveolar carcinomas or adenomas	Multistage model with linear extrapolation from the point of departure (BMDL10)	per µg /m³	1x10^-8	Inhalation
197	2,4-Dichlorophenol	120-83-2	Not Assessed under the IRIS program.
198	4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB)	94-82-6	Not Assessed under the IRIS program.
199	2,4-Dichlorophenoxyacetic acid (2,4-D)	94-75-7	Not Assessed under the IRIS program.
200	1,2-Dichloropropane	78-87-5	Not Assessed under the IRIS program.
201	2,3-Dichloropropanol	616-23-9	Not Assessed under the IRIS program.
202	1,3-Dichloropropene	542-75-6	Bronchioalveolar adenoma	Linearized multistage model, extra risk	per µg /m³	4x10^-6	Inhalation
203	Dichlorvos	62-73-7	Not Assessed under the IRIS program.
204	Dicofol	115-32-2	Not Assessed under the IRIS program.
205	Dieldrin	60-57-1	Liver carcinoma	Linearized multistage procedure, extra risk	per µg /m³	4.6x10^-3	Oral, Diet
206	Diesel engine exhaust	NA	Information reviewed but value not estimated. Refer to IRIS Summary.
207	Diethyl phthalate	84-66-2	Not Assessed under the IRIS program.
208	Diethyl sulfate	64-67-5	Not Assessed under the IRIS program.
209	Diethyl-p-nitrophenylphosphate	311-45-5	Not Assessed under the IRIS program.
210	Diethylene glycol dinitrate (DEGDN)	693-21-0	Not Assessed under the IRIS program.
211	Difenzoquat	43222-48-6	Not Assessed under the IRIS program.
212	Diflubenzuron	35367-38-5	Not Assessed under the IRIS program.
213	1,1-Difluoroethane	75-37-6	Not Assessed under the IRIS program.
214	Diisopropyl methylphosphonate (DIMP)	1445-75-6	Not Assessed under the IRIS program.
215	Dimethipin	55290-64-7	Not Assessed under the IRIS program.
216	Dimethoate	60-51-5	Not Assessed under the IRIS program.
217	Dimethyl phthalate	131-11-3	Not Assessed under the IRIS program.
218	Dimethyl sulfate	77-78-1	Not Assessed under the IRIS program.
219	Dimethyl terephthalate (DMT)	120-61-6	Not Assessed under the IRIS program.
220	Dimethylamine	124-40-3	Not Assessed under the IRIS program.
221	N-N-Dimethylaniline	121-69-7	Not Assessed under the IRIS program.
222	3,3-Dimethylbenzidine	119-93-7	Not Assessed under the IRIS program.
223	N,N-Dimethylformamide	68-12-2	Not Assessed under the IRIS program.
224	3,4-Dimethylphenol	95-65-8	Not Assessed under the IRIS program.
225	2,6-Dimethylphenol	576-26-1	Not Assessed under the IRIS program.
226	2,4-Dimethylphenol	105-67-9	Not Assessed under the IRIS program.
227	4,6-Dinitro-o-cyclohexyl phenol	131-89-5	Not Assessed under the IRIS program.
228	m-Dinitrobenzene	99-65-0	Not Assessed under the IRIS program.
229	o-Dinitrobenzene	528-29-0	Not Assessed under the IRIS program.
230	2,4-Dinitrophenol	51-28-5	Not Assessed under the IRIS program.
231	2,4-Dinitrotoluene	121-14-2	Not Assessed under the IRIS program.
232	2,4-/2,6-Dinitrotoluene mixture	NA	Not Assessed under the IRIS program.
233	Dinoseb	88-85-7	Not Assessed under the IRIS program.
234	1,4-Dioxane	123-91-1	Information reviewed but value not estimated. Refer to IRIS Summary.
235	Diphenamid	957-51-7	Not Assessed under the IRIS program.
236	Diphenylamine	122-39-4	Not Assessed under the IRIS program.
237	1,2-Diphenylhydrazine	122-66-7	Hepatocellular carcinomas and neoplastic liver nodules	Linearized multistage procedure, extra risk	per µg /m³	2.2x10^-4	Oral, Diet
238	Diquat	85-00-7	Not Assessed under the IRIS program.
239	Disulfoton	298-04-4	Not Assessed under the IRIS program.
240	1,4-Dithiane	505-29-3	Not Assessed under the IRIS program.
241	Diuron	330-54-1	Not Assessed under the IRIS program.
242	Dodine	2439-10-3	Not Assessed under the IRIS program.
243	Endosulfan	115-29-7	Not Assessed under the IRIS program.
244	Endothall	145-73-3	Not Assessed under the IRIS program.
245	Endrin	72-20-8	Not Assessed under the IRIS program.
246	Epichlorohydrin	106-89-8	Nasal cavity tumors	Linearized multistage procedure, extra risk	per µg /m³	1.2x10^-6	Inhalation
247	1,2-Epoxybutane (EBU)	106-88-7	Not Assessed under the IRIS program.
248	Ethephon	16672-87-0	Not Assessed under the IRIS program.
249	Ethion	563-12-2	Not Assessed under the IRIS program.
250	2-Ethoxyethanol	110-80-5	Not Assessed under the IRIS program.
251	Ethyl acetate	141-78-6	Not Assessed under the IRIS program.
252	Ethyl carbamate	51-79-6	Not Assessed under the IRIS program.
253	Ethyl chloride	75-00-3	Not Assessed under the IRIS program.
254	S-Ethyl dipropylthiocarbamate (EPTC)	759-94-4	Not Assessed under the IRIS program.
255	Ethyl ether	60-29-7	Not Assessed under the IRIS program.
256	Ethyl p-nitrophenyl phenylphosphorothioate (EPN)	2104-64-5	Not Assessed under the IRIS program.
257	Ethylbenzene	100-41-4	Not Assessed under the IRIS program.
258	Ethylene diamine	107-15-3	Not Assessed under the IRIS program.
259	Ethylene glycol	107-21-1	Not Assessed under the IRIS program.
260	Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol)	111-76-2	Information reviewed but value not estimated. Refer to IRIS Summary.
261	Ethylene thiourea (ETU)	96-45-7	Not Assessed under the IRIS program.
262	Ethyleneimine	151-56-4	Not Assessed under the IRIS program.
263	Ethylphthalyl ethylglycolate (EPEG)	84-72-0	Not Assessed under the IRIS program.
264	Express	101200-48-0	Not Assessed under the IRIS program.
265	Fenamiphos	22224-92-6	Not Assessed under the IRIS program.
266	Fluometuron	2164-17-2	Not Assessed under the IRIS program.
267	Fluoranthene	206-44-0	Not Assessed under the IRIS program.
268	Fluorene	86-73-7	Not Assessed under the IRIS program.
269	Fluorine (soluble fluoride)	7782-41-4	Not Assessed under the IRIS program.
270	Fluridone	59756-60-4	Not Assessed under the IRIS program.
271	Flurprimidol	56425-91-3	Not Assessed under the IRIS program.
272	Flutolanil	66332-96-5	Not Assessed under the IRIS program.
273	Fluvalinate	69409-94-5	Not Assessed under the IRIS program.
274	Folpet	133-07-3	Not Assessed under the IRIS program.
275	Fomesafen	72178-02-0	Not Assessed under the IRIS program.
276	Fonofos	944-22-9	Not Assessed under the IRIS program.
277	Formaldehyde	50-00-0	Squamous cell carcinoma	Linearized multistage procedure, additional risk	per µg /m³	1.3x10^-5	Inhalation
278	Formic acid	64-18-6	Not Assessed under the IRIS program.
279	Fosetyl-al	39148-24-8	Not Assessed under the IRIS program.
280	Furan	110-00-9	Not Assessed under the IRIS program.
281	Furfural	98-01-1	Not Assessed under the IRIS program.
282	Furmecyclox	60568-05-0	Not Assessed under the IRIS program.
283	Glufosinate-ammonium	77182-82-2	Not Assessed under the IRIS program.
284	Glycidaldehyde	765-34-4	Not Assessed under the IRIS program.
285	Glyphosate	1071-83-6	Not Assessed under the IRIS program.
286	Haloxyfop-methyl	69806-40-2	Not Assessed under the IRIS program.
287	Harmony	79277-27-3	Not Assessed under the IRIS program.
288	Heptachlor	76-44-8	Hepatocellular carcinomas	Linearized multistage procedure, extra risk	per µg/m³	1.3x10^-3	Oral, Diet
289	Heptachlor epoxide	1024-57-3	Hepatocellular carcinomas	Linearized multistage procedure, extra risk	per µg/m³	2.6x10^-3	Oral, Diet
290	n-Heptane	142-82-5	Not Assessed under the IRIS program.
291	Hexabromobenzene	87-82-1	Not Assessed under the IRIS program.
292	Hexabromodiphenyl ether	36483-60-0	Not Assessed under the IRIS program.
293	2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153)	68631-49-2	Not Assessed under the IRIS program.
294	Hexachlorobenzene	118-74-1	Hepatocellular carcinoma	Linearized multistage, extra risk	per µg /m³	4.6x10^-4	Oral, Diet
295	Hexachlorobutadiene	87-68-3	Renal tubular adenomas and adenocarcinomas	Linearized multistage procedure, extra risk	per µg /m³	2.2x10^-5	Oral, Diet
296	alpha-Hexachlorocyclohexane (alpha-HCH)	319-84-6	Hepatic nodules and hepatocellular carcinomas	Linearized multistage procedure, extra risk	per µg /m³	1.8x10^-3	Oral, Diet
297	beta-Hexachlorocyclohexane (beta-HCH)	319-85-7	Hepatic nodules and hepatocellular carcinomas	Linearized multistage procedure, extra risk	per µg /m³	5.3x10^-4	Oral, Diet
298	delta-Hexachlorocyclohexane (delta-HCH)	319-86-8	Not Assessed under the IRIS program.
299	epsilon-Hexachlorocyclohexane (epsilon-HC)	6108-10-7	Not Assessed under the IRIS program.
300	gamma-Hexachlorocyclohexane (gamma-HCH)	58-89-9	Not Assessed under the IRIS program.
301	technical Hexachlorocyclohexane (t-HCH)	608-73-1	Liver nodules and hepatocellular carcinomas	Linearized multistage procedure	per µg /m³	5.1x10^-4	Oral, Diet
302	Hexachlorocyclopentadiene (HCCPD)	77-47-4	Not Assessed under the IRIS program.
303	Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD	57653-85-7	Liver tumors (adenomas and carcinomas; neoplastic nodules and hepatocellular carcinomas)	Linearized multistage procedure, extra risk	per µg /m³	1.3	Oral, Gavage
304	Hexachloroethane	67-72-1	Information reviewed but value not estimated. Refer to IRIS Summary.
305	Hexachlorophene	70-30-4	Not Assessed under the IRIS program.
306	Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)	121-82-4	Not Assessed under the IRIS program.
307	1,6-Hexamethylene diisocyanate	822-06-0	Not Assessed under the IRIS program.
308	n-Hexane	110-54-3	Not Assessed under the IRIS program.
309	2-Hexanone	591-78-6	Not Assessed under the IRIS program.
310	Hexazinone	51235-04-2	Not Assessed under the IRIS program.
311	Hydrazine/Hydrazine sulfate	302-01-2	Nasal cavity adenoma or adenocarcinoma	Linearized multistage procedure, extra risk	per µg /m³	4.9x10^-3	Inhalation
312	Hydrogen Cyanide and Cyanide Salts	Various	Not Assessed under the IRIS program.
313	Hydrogen chloride	7647-01-0	Not Assessed under the IRIS program.
314	Hydrogen sulfide	7783-06-4	Not Assessed under the IRIS program.
315	Hydroquinone	123-31-9	Not Assessed under the IRIS program.
316	Imazalil	35554-44-0	Not Assessed under the IRIS program.
317	Imazaquin	81335-37-7	Not Assessed under the IRIS program.
318	Indeno[1,2,3-cd]pyrene	193-39-5	Not Assessed under the IRIS program.
319	Iprodione	36734-19-7	Not Assessed under the IRIS program.
320	Isobutyl alcohol	78-83-1	Not Assessed under the IRIS program.
321	Isophorone	78-59-1	Not Assessed under the IRIS program.
322	Isopropalin	33820-53-0	Not Assessed under the IRIS program.
323	Isopropyl methyl phosphonic acid (IMPA)	1832-54-8	Not Assessed under the IRIS program.
324	Isoxaben	82558-50-7	Not Assessed under the IRIS program.
325	Lactofen	77501-63-4	Not Assessed under the IRIS program.
326	Lead and compounds (inorganic)	7439-92-1	Not Assessed under the IRIS program.
327	d-Limonene	5989-27-5	Not Assessed under the IRIS program.
328	Linuron	330-55-2	Not Assessed under the IRIS program.
329	Londax	83055-99-6	Not Assessed under the IRIS program.
330	Malathion	121-75-5	Not Assessed under the IRIS program.
331	Maleic anhydride	108-31-6	Not Assessed under the IRIS program.
332	Maleic hydrazide	123-33-1	Not Assessed under the IRIS program.
333	Maneb	12427-38-2	Not Assessed under the IRIS program.
334	Manganese	7439-96-5	Not Assessed under the IRIS program.
335	Mepiquat chloride	24307-26-4	Not Assessed under the IRIS program.
336	Mercuric chloride (HgCl2)	7487-94-7	Not Assessed under the IRIS program.
337	Mercury, elemental	7439-97-6	Not Assessed under the IRIS program.
338	Merphos	150-50-5	Not Assessed under the IRIS program.
339	Merphos oxide	78-48-8	Not Assessed under the IRIS program.
340	Metalaxyl	57837-19-1	Not Assessed under the IRIS program.
341	Methacrylonitrile	126-98-7	Not Assessed under the IRIS program.
342	Methamidophos	10265-92-6	Not Assessed under the IRIS program.
343	Methanol	67-56-1	Not Assessed under the IRIS program.
344	Methidathion	950-37-8	Not Assessed under the IRIS program.
345	Methomyl	16752-77-5	Not Assessed under the IRIS program.
346	Methoxychlor	72-43-5	Not Assessed under the IRIS program.
347	2-Methoxyethanol	109-86-4	Not Assessed under the IRIS program.
348	Methyl acrylate	96-33-3	Not Assessed under the IRIS program.
349	Methyl chloride	74-87-3	Not Assessed under the IRIS program.
350	Methyl chlorocarbonate	79-22-1	Not Assessed under the IRIS program.
351	Methyl ethyl ketone (MEK)	78-93-3	Not Assessed under the IRIS program.
352	Methyl iodide	74-88-4	Not Assessed under the IRIS program.
353	Methyl isobutyl ketone (MIBK)	108-10-1	Not Assessed under the IRIS program.
354	Methyl isocyanate	624-83-9	Not Assessed under the IRIS program.
355	Methyl methacrylate	80-62-6	Not Assessed under the IRIS program.
356	Methyl parathion	298-00-0	Not Assessed under the IRIS program.
357	Methyl tert-butyl ether (MTBE)	1634-04-4	Not Assessed under the IRIS program.
358	4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB)	94-81-5	Not Assessed under the IRIS program.
359	2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP)	93-65-2	Not Assessed under the IRIS program.
360	2-Methyl-4-chlorophenoxyacetic acid (MCPA)	94-74-6	Not Assessed under the IRIS program.
361	Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI)	101-68-8	Not Assessed under the IRIS program.
362	4,4'-Methylene bis(N,N'-dimethyl)aniline	101-61-1	Not Assessed under the IRIS program.
363	Methylmercury (MeHg)	22967-92-6	Not Assessed under the IRIS program.
364	2-Methylnaphthalene	91-57-6	Not Assessed under the IRIS program.
365	2-Methylphenol	95-48-7	Not Assessed under the IRIS program.
366	4-Methylphenol	106-44-5	Not Assessed under the IRIS program.
367	3-Methylphenol	108-39-4	Not Assessed under the IRIS program.
368	Metolachlor	51218-45-2	Not Assessed under the IRIS program.
369	Metribuzin	21087-64-9	Not Assessed under the IRIS program.
370	Mirex	2385-85-5	Not Assessed under the IRIS program.
371	Molinate	2212-67-1	Not Assessed under the IRIS program.
372	Molybdenum	7439-98-7	Not Assessed under the IRIS program.
373	Monochloramine	10599-90-3	Not Assessed under the IRIS program.
374	Naled	300-76-5	Not Assessed under the IRIS program.
375	Naphthalene	91-20-3	Information reviewed but value not estimated. Refer to IRIS Summary.
376	Napropamide	15299-99-7	Not Assessed under the IRIS program.
377	Nickel carbonyl	13463-39-3	Not Assessed under the IRIS program.
378	Nickel refinery dust	NA	Lung cancer	Additive and multiplicative	per µg /m³	2.4x10-4	Inhalation
379	Nickel subsulfide	12035-72-2	Lung cancer	Additive and multiplicative	per µg /m³	4.8x10^-4	Inhalation
380	Nickel, soluble salts	NA	Not Assessed under the IRIS program.
381	Nitrapyrin	1929-82-4	Not Assessed under the IRIS program.
382	Nitrate	14797-55-8	Not Assessed under the IRIS program.
383	Nitric oxide	10102-43-9	Not Assessed under the IRIS program.
384	Nitrite	14797-65-0	Not Assessed under the IRIS program.
385	Nitrobenzene	98-95-3	Liver hepatocellular adenomas or carcinomas, kidney tubular adenomas or carcinomas, thyroid follicular cell adenomas or carcinomas	Multistage model with linear extrapolation from the POD (LEC10).	per µg /m³	4x10^-5	Inhalation
386	Nitrogen dioxide	10102-44-0	Not Assessed under the IRIS program.
387	Nitroguanidine	556-88-7	Not Assessed under the IRIS program.
388	p-Nitrophenol	100-02-7	Not Assessed under the IRIS program.
389	2-Nitropropane	79-46-9	Not Assessed under the IRIS program.
390	N-Nitroso-N-methylethylamine	10595-95-6	Not Assessed under the IRIS program.
391	N-Nitroso-di-n-butylamine	924-16-3	Bladder and esophagus tumors	Linearized multistage procedure, extra risk	per µg /m³	1.6x10^-3	Oral, Drinking water
392	N-Nitrosodi-N-propylamine	621-64-7	Not Assessed under the IRIS program.
393	N-Nitrosodiethanolamine	1116-54-7	Not Assessed under the IRIS program.
394	N-Nitrosodiethylamine	55-18-5	Liver tumors	Weibull, extra risk	per µg /m³	4.3x10^-2	Oral, Drinking water
395	N-Nitrosodimethylamine	62-75-9	Liver tumors	Weibull, extra risk	per µg /m³	1.4x10^-2	Oral, Drinking water
396	N-Nitrosodiphenylamine	86-30-6	Not Assessed under the IRIS program.
397	N-Nitrosopyrrolidine	930-55-2	Hepatocellular carcinoma and adenoma	Linearized multistage procedure, extra risk	per µg /m³	6.1x10^-4	Oral, Diet
398	Nonabromodiphenyl ether	63936-56-1	Not Assessed under the IRIS program.
399	Norflurazon	27314-13-2	Not Assessed under the IRIS program.
400	NuStar	85509-19-9	Not Assessed under the IRIS program.
401	Octabromodiphenyl ether	32536-52-0	Not Assessed under the IRIS program.
402	Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX)	2691-41-0	Not Assessed under the IRIS program.
403	Oryzalin	19044-88-3	Not Assessed under the IRIS program.
404	Oxadiazon	19666-30-9	Not Assessed under the IRIS program.
405	Oxamyl	23135-22-0	Not Assessed under the IRIS program.
406	Oxyfluorfen	42874-03-3	Not Assessed under the IRIS program.
407	Paclobutrazol	76738-62-0	Not Assessed under the IRIS program.
408	Paraquat	1910-42-5	Not Assessed under the IRIS program.
409	Parathion	56-38-2	Not Assessed under the IRIS program.
410	Pendimethalin	40487-42-1	Not Assessed under the IRIS program.
411	Pentabromodiphenyl ether	32534-81-9	Not Assessed under the IRIS program.
412	2,2',4,4',5-Pentabromodiphenyl ether (BDE-99)	60348-60-9	Not Assessed under the IRIS program.
413	Pentachlorobenzene	608-93-5	Not Assessed under the IRIS program.
414	Pentachlorocyclopentadiene	25329-35-5	Not Assessed under the IRIS program.
415	Pentachloronitrobenzene (PCNB)	82-68-8	Not Assessed under the IRIS program.
416	Pentachlorophenol	87-86-5	Not Assessed under the IRIS program.
417	Pentafluoroethane	354-33-6	Not Assessed under the IRIS program.
418	Perchlorate (ClO4) and Perchlorate Salts	7790-98-9	Not Assessed under the IRIS program.
419	Permethrin	52645-53-1	Not Assessed under the IRIS program.
420	Phenanthrene	85-01-8	Not Assessed under the IRIS program.
421	Phenmedipham	13684-63-4	Not Assessed under the IRIS program.
422	Phenol	108-95-2	Not Assessed under the IRIS program.
423	m-Phenylenediamine	108-45-2	Not Assessed under the IRIS program.
424	Phenylmercuric acetate	62-38-4	Not Assessed under the IRIS program.
425	Phosalone	2310-17-0	Not Assessed under the IRIS program.
426	Phosgene	75-44-5	Not Assessed under the IRIS program.
427	Phosmet	732-11-6	Not Assessed under the IRIS program.
428	Phosphine	7803-51-2	Not Assessed under the IRIS program.
429	Phosphoric acid	7664-38-2	Not Assessed under the IRIS program.
430	Phthalic anhydride	85-44-9	Not Assessed under the IRIS program.
431	Picloram	1918-02-1	Not Assessed under the IRIS program.
432	Pirimiphos-methyl	29232-93-7	Not Assessed under the IRIS program.
433	Polychlorinated biphenyls (PCBs)	1336-36-3	Liver hepatocellular adenomas, carcinomas, cholangiomas, or cholangiocarcinomas	Linear extrapolation below LED10s	per µg /m³	1x10^-4	Oral, Diet
434	Potassium cyanide	151-50-8	Not Assessed under the IRIS program.
435	Potassium silver cyanide	506-61-6	Not Assessed under the IRIS program.
436	Prochloraz	67747-09-5	Not Assessed under the IRIS program.
437	Prometon	1610-18-0	Not Assessed under the IRIS program.
438	Prometryn	7287-19-6	Not Assessed under the IRIS program.
439	Pronamide	23950-58-5	Not Assessed under the IRIS program.
440	Propachlor	1918-16-7	Not Assessed under the IRIS program.
441	Propanil	709-98-8	Not Assessed under the IRIS program.
442	Propargite	2312-35-8	Not Assessed under the IRIS program.
443	Propargyl alcohol	107-19-7	Not Assessed under the IRIS program.
444	Propazine	139-40-2	Not Assessed under the IRIS program.
445	Propham	122-42-9	Not Assessed under the IRIS program.
446	Propiconazole	60207-90-1	Not Assessed under the IRIS program.
447	beta-Propiolactone	57-57-8	Not Assessed under the IRIS program.
448	Propionaldehyde	123-38-6	Not Assessed under the IRIS program.
449	Propylene glycol	57-55-6	Not Assessed under the IRIS program.
450	Propylene glycol monoethyl ether	52125-53-8	Not Assessed under the IRIS program.
451	Propylene glycol monomethyl ether (PGME)	107-98-2	Not Assessed under the IRIS program.
452	Propylene oxide	75-56-9	Nasal cavity hemangioma or hemangiosarcoma	Linearized multistage procedure, extra risk	per µg /m³	3.7x10^-6	Inhalation
453	Propyleneimine	75-55-8	Not Assessed under the IRIS program.
454	Pursuit	81335-77-5	Not Assessed under the IRIS program.
455	Pydrin	51630-58-1	Not Assessed under the IRIS program.
456	Pyrene	129-00-0	Not Assessed under the IRIS program.
457	Pyridine	110-86-1	Not Assessed under the IRIS program.
458	Quinalphos	13593-03-8	Not Assessed under the IRIS program.
459	Quinoline	91-22-5	Information reviewed but value not estimated. Refer to IRIS Summary.
460	Quinone	106-51-4	Not Assessed under the IRIS program.
461	Radium 226,228	7440-14-4	Not Assessed under the IRIS program.
462	Radon 222	14859-67-7	Not Assessed under the IRIS program.
463	Refractory ceramic fibers	NA	Information reviewed but value not estimated. Refer to IRIS Summary.
464	Resmethrin	10453-86-8	Not Assessed under the IRIS program.
465	Rotenone	83-79-4	Not Assessed under the IRIS program.
466	Savey	78587-05-0	Not Assessed under the IRIS program.
467	Selenious acid	7783-00-8	Not Assessed under the IRIS program.
468	Selenium and Compounds	7782-49-2	Not Assessed under the IRIS program.
469	Selenium sulfide	7446-34-6	Not Assessed under the IRIS program.
470	Selenourea	630-10-4	Not Assessed under the IRIS program.
471	Sethoxydim	74051-80-2	Not Assessed under the IRIS program.
472	Silver	7440-22-4	Not Assessed under the IRIS program.
473	Silver cyanide	506-64-9	Not Assessed under the IRIS program.
474	Simazine	122-34-9	Not Assessed under the IRIS program.
475	Sodium azide	26628-22-8	Not Assessed under the IRIS program.
476	Sodium cyanide	143-33-9	Not Assessed under the IRIS program.
477	Sodium diethyldithiocarbamate	148-18-5	Not Assessed under the IRIS program.
478	Sodium fluoroacetate	62-74-8	Not Assessed under the IRIS program.
479	Strontium	7440-24-6	Not Assessed under the IRIS program.
480	Strychnine	57-24-9	Not Assessed under the IRIS program.
481	Styrene	100-42-5	Not Assessed under the IRIS program.
482	Systhane	88671-89-0	Not Assessed under the IRIS program.
483	Tebuthiuron	34014-18-1	Not Assessed under the IRIS program.
484	Terbacil	5902-51-2	Not Assessed under the IRIS program.
485	Terbutryn	886-50-0	Not Assessed under the IRIS program.
486	Tetrabromodiphenyl ether	40088-47-9	Not Assessed under the IRIS program.
487	2,2',4,4'-Tetrabromodiphenyl ether (BDE-47)	5436-43-1	Not Assessed under the IRIS program.
488	1,2,4,5-Tetrachlorobenzene	95-94-3	Not Assessed under the IRIS program.
489	Tetrachlorocyclopentadiene	695-77-2	Not Assessed under the IRIS program.
490	1,1,1,2-Tetrachloroethane	630-20-6	Hepatocellular adenoma or carcinoma	Linearized multistage procedure, extra risk	per µg /m³	7.4x10^-6	Oral, Gavage
491	1,1,2,2-Tetrachloroethane	79-34-5	Information reviewed but value not estimated. Refer to IRIS Summary.
492	Tetrachloroethylene	127-18-4	Not Assessed under the IRIS program.
493	2,3,4,6-Tetrachlorophenol	58-90-2	Not Assessed under the IRIS program.
494	Tetrachlorovinphos	961-11-5	Not Assessed under the IRIS program.
495	Tetraethyl lead	78-00-2	Not Assessed under the IRIS program.
496	Tetraethyldithiopyrophosphate	3689-24-5	Not Assessed under the IRIS program.
497	1,1,1,2-Tetrafluoroethane	811-97-2	Not Assessed under the IRIS program.
498	Thallium (I), soluble salts	Various	Not Assessed under the IRIS program.
499	Thallium acetate	563-68-8	Not Assessed under the IRIS program.
500	Thallium carbonate	6533-73-9	Not Assessed under the IRIS program.
501	Thallium chloride	7791-12-0	Not Assessed under the IRIS program.
502	Thallium nitrate	10102-45-1	Not Assessed under the IRIS program.
503	Thallium oxide	1314-32-5	Not Assessed under the IRIS program.
504	Thallium selenite	12039-52-0	Not Assessed under the IRIS program.
505	Thallium(I) sulfate	7446-18-6	Not Assessed under the IRIS program.
506	Thiobencarb	28249-77-6	Not Assessed under the IRIS program.
507	Thiophanate-methyl	23564-05-8	Not Assessed under the IRIS program.
508	Thiram	137-26-8	Not Assessed under the IRIS program.
509	Toluene	108-88-3	Not Assessed under the IRIS program.
510	2,4-/2,6-Toluene diisocyanate mixture (TDI)	26471-62-5	Not Assessed under the IRIS program.
511	Toxaphene	8001-35-2	Hepatocellular carcinomas and neoplastic nodules	Linearized multistage procedure, extra risk	per µg /m³	3.2x10^-4	Oral, Diet
512	Tralomethrin	66841-25-6	Not Assessed under the IRIS program.
513	Triallate	2303-17-5	Not Assessed under the IRIS program.
514	Triasulfuron	82097-50-5	Not Assessed under the IRIS program.
515	1,2,4-Tribromobenzene	615-54-3	Not Assessed under the IRIS program.
516	Tribromochloromethane	594-15-0	Not Assessed under the IRIS program.
517	Tribromodiphenyl ether	49690-94-0	Not Assessed under the IRIS program.
518	Tributyltin oxide (TBTO)	56-35-9	Not Assessed under the IRIS program.
519	1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113)	76-13-1	Not Assessed under the IRIS program.
520	Trichloroacetic acid	76-03-9	Information reviewed but value not estimated. Refer to IRIS Summary.
521	1,2,4-Trichlorobenzene	120-82-1	Not Assessed under the IRIS program.
522	Trichlorocyclopentadiene	77323-84-3	Not Assessed under the IRIS program.
523	1,1,2-Trichloroethane	79-00-5	Hepatocellular carcinoma	Linearized multistage procedure, extra risk	per µg /m³	1.6x10^-5	Oral, Gavage
524	1,1,1-Trichloroethane	71-55-6	Information reviewed but value not estimated. Refer to IRIS Summary.
525	Trichloroethylene	79-01-6	Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors	Low-dose linear extrapolation from the point of departure (LEC01) with a factor of 4 applied to include non-Hodgkin's lymphoma (NHL) and liver cancer risks, combined risk	per µg /m³	4.1x10^-6	Inhalation
526	Trichlorofluoromethane	75-69-4	Not Assessed under the IRIS program.
527	2,4,5-Trichlorophenol	95-95-4	Not Assessed under the IRIS program.
528	2,4,6-Trichlorophenol	88-06-2	Leukemia	Linearized multistage procedure, extra risk	per µg /m³	3.1x10^-6	Oral,Diet
529	2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP)	93-72-1	Not Assessed under the IRIS program.
530	2,4,5-Trichlorophenoxyacetic acid (2,4,5-T)	93-76-5	Not Assessed under the IRIS program.
531	1,1,2-Trichloropropane	598-77-6	Not Assessed under the IRIS program.
532	1,2,3-Trichloropropane	96-18-4	Not Assessed under the IRIS program.
533	Tricresol	1319-77-3	Not Assessed under the IRIS program.
534	Tridiphane	58138-08-2	Not Assessed under the IRIS program.
535	Triethylamine	121-44-8	Not Assessed under the IRIS program.
536	Triethylene glycol monobutyl ether	143-22-6	Not Assessed under the IRIS program.
537	Triethylene glycol monoethyl ether	112-50-5	Not Assessed under the IRIS program.
538	Trifluralin	1582-09-8	Not Assessed under the IRIS program.
539	2,2,4-Trimethylpentane	540-84-1	Not Assessed under the IRIS program.
540	1,3,5-Trinitrobenzene	99-35-4	Not Assessed under the IRIS program.
541	2,4,6-Trinitrotoluene (TNT)	118-96-7	Not Assessed under the IRIS program.
542	Uranium, natural	7440-61-1	Not Assessed under the IRIS program.
543	Uranium, soluble salts	NA	Not Assessed under the IRIS program.
544	Urea	57-13-6	Not Assessed under the IRIS program.
545	Vanadium pentoxide	1314-62-1	Not Assessed under the IRIS program.
546	Vernam	1929-77-7	Not Assessed under the IRIS program.
547	Vinclozolin	50471-44-8	Not Assessed under the IRIS program.
548	Vinyl acetate	108-05-4	Not Assessed under the IRIS program.
549	Vinyl bromide	593-60-2	Not Assessed under the IRIS program.
550	Vinyl chloride	75-01-4	Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules	LMS method	per µg /m³	4.4x10^-6	Inhalation
551	Vinyl chloride	75-01-4	Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules	LED 10/ linear method	per µg /m³	4.4x10^-6	Inhalation
552	Vinyl chloride	75-01-4	Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules	LMS method	per µg /m³	8.8x10^-6	Inhalation
553	Vinyl chloride	75-01-4	Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules	LED 10/ linear method	per µg /m³	8.8x10^-6	Inhalation
554	Warfarin	81-81-2	Not Assessed under the IRIS program.
555	White phosphorus	7723-14-0	Not Assessed under the IRIS program.
556	Xylenes	1330-20-7	Not Assessed under the IRIS program.
557	Zinc and Compounds	7440-66-6	Not Assessed under the IRIS program.
558	Zinc cyanide	557-21-1	Not Assessed under the IRIS program.
559	Zinc phosphide	1314-84-7	Not Assessed under the IRIS program.
560	Zineb	12122-67-7	Not Assessed under the IRIS program.

References

Related files

@@ Line 225: / Line 225: @@
 Carbofuran|1563-66-2|Not Assessed under the IRIS program.||||||
 Carbon disulfide|75-15-0|Peripheral nervous system dysfunction|mg /m<sup>3</sup>|7x10<sup>-1</sup>|BMC<sub>10</sub> (HEC)|19.7|Medium|0217
-Carbon tetrachloride|56-23-5|Not Assessed under the IRIS program.|Fatty changes in the liver|mg /m<sup>3</sup>|0.1|BMCL<sub>10</sub> (HEC)|14.3|0020
+Carbon tetrachloride|56-23-5|Fatty changes in the liver|mg /m<sup>3</sup>|0.1|BMCL<sub>10</sub> (HEC)|14.3|Medium|0020
 Carbonyl sulfide|463-58-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0617
 Carbosulfan|55285-14-8|Not Assessed under the IRIS program.||||||
@@ Line 426: / Line 426: @@
 Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)|121-82-4|Not Assessed under the IRIS program.||||||
 ,6-Hexamethylene diisocyanate|822-06-0|Degeneration of olfactory epithelium|mg /m<sup>3</sup|1x10<sup>-5</sup>|NOAEL (HEC)|0.001|Medium|0638
-n-Hexane|110-54-3|.||||||
+n-Hexane|110-54-3|Peripheral neuropathy (decreased MCV at 12 weeks)|mg /m<sup>3</sup>|7x10<sup>-1</sup>|BMCL (HEC)|215|Medium|0486
--Hexanone|591-78-6|.||||||
+-Hexanone|591-78-6|Motor conduction velocity of the sciatic-tibial nerve|mg /m<sup>3</sup>|3x10<sup>-2</sup>|BMCL<sub>05</sub> (HEC)|90|Low|1019
 Hexazinone|51235-04-2|Not Assessed under the IRIS program.||||||
 Hydrazine/Hydrazine sulfate|302-01-2|Not Assessed under the IRIS program.||||||
-Hydrogen Cyanide and Cyanide Salts|Various|.||||||
+Hydrogen Cyanide and Cyanide Salts|Various|Thyroid enlargement and altered iodide uptake|mg /m<sup>3</sup>|0.0008|LOAEL (ADJ)|2.5|Low/Medium|0060
-Hydrogen chloride|7647-01-0|.||||||
+Hydrogen chloride|7647-01-0|Hyperplasia of nasal mucosa larynx and trachea|mg /m<sup>3</sup>|2x10<sup>-2</sup>|LOAEL (HEC)|6.1|Low|0396
-Hydrogen sulfide|7783-06-4|.||||||
+Hydrogen sulfide|7783-06-4|Nasal lesions of the olfactory mucosa|mg /m<sup>3</sup>|2x10<sup>-3</sup>|NOAEL (HEC)|0.64|Medium/High|0061
 Hydroquinone|123-31-9|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
 Imazalil|35554-44-0|Not Assessed under the IRIS program.||||||
@@ Line 452: / Line 452: @@
 Maleic hydrazide|123-33-1|Not Assessed under the IRIS program.||||||
 Maneb|12427-38-2|Not Assessed under the IRIS program.||||||
-Manganese|7439-96-5|.||||||
+Manganese|7439-96-5|Impairment of neurobehavioral function (other effect: Impairment of neurobehavioral function)|mg /m<sup>3</sup>|5x10<sup>-5</sup>|LOAEL (HEC)|0.05|Medium|0373
 Mepiquat chloride|24307-26-4|Not Assessed under the IRIS program.||||||
 Mercuric chloride (HgCl2)|7487-94-7|Not Assessed under the IRIS program.||||||
-Mercury, elemental|7439-97-6|.||||||
+Mercury, elemental|7439-97-6|Hand tremor; increases in memory disturbances; slight subjective and objective evidence of autonomic dysfunction|mg /m<sup>3</sup>|3x10<sup>-4</sup>|LOAEL (ADJ)|0.009|Medium|0370
 Merphos|150-50-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
 Merphos oxide|78-48-8|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
@@ Line 465: / Line 465: @@
 Methomyl|16752-77-5|Not Assessed under the IRIS program.||||||
 Methoxychlor|72-43-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
--Methoxyethanol|109-86-4|.||||||
+-Methoxyethanol|109-86-4|Testicular effects|mg /m<sup>3</sup>|2x10<sup>-2</sup>|NOAEL (HEC)|17|Medium|0525
 Methyl acrylate|96-33-3|Not Assessed under the IRIS program.||||||
-Methyl chloride|74-87-3|.||||||
+Methyl chloride|74-87-3|Cerebellar lesions|mg /m<sup>3</sup>|9x10<sup>-2</sup>|NOAEL (HEC)|94.6|Medium|1003
 Methyl chlorocarbonate|79-22-1|Not Assessed under the IRIS program.||||||
-Methyl ethyl ketone (MEK)|78-93-3|.||||||
+Methyl ethyl ketone (MEK)|78-93-3|Developmental toxicity (skeletal variations)|mg /m<sup>3</sup>|5|LEC (HEC)|1517|Medium|0071
 Methyl iodide|74-88-4|Not Assessed under the IRIS program.||||||
-Methyl isobutyl ketone (MIBK)|108-10-1|.||||||
+Methyl isobutyl ketone (MIBK)|108-10-1|Reduced fetal body weight, skeletal variations, and increased fetal death in mice, and skeletal variations in rats|mg /m<sup>3</sup>|3|NOAEL (HEC)|1026|Low/Medium|0173
 Methyl isocyanate|624-83-9|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
-Methyl methacrylate|80-62-6|.||||||
+Methyl methacrylate|80-62-6|Degeneration/ atrophy of olfactory epithelium (male rats)|mg /m<sup>3</sup>|7x10<sup>-1</sup>|BMC<sub>10</sub> (HEC)|7.2|Medium/High|1000
 Methyl parathion|298-00-0|Not Assessed under the IRIS program.||||||
-Methyl tert-butyl ether (MTBE)|1634-04-4|.||||||
+Methyl tert-butyl ether (MTBE)|1634-04-4|Increased absolute and relative liver and kidney weights and increased severity of spontaneous renal lesions (females), increased prostration (females), and swollen periocular tissue (males and females)|mg /m<sup>3</sup>|3|NOAEL (HEC)|259|Medium|0545
 -(2-Methyl-4-chlorophenoxy) butyric acid (MCPB)|94-81-5|Not Assessed under the IRIS program.||||||
 -(2-Methyl-4-chlorophenoxy)propionic acid (MCPP)|93-65-2|Not Assessed under the IRIS program.||||||
 -Methyl-4-chlorophenoxyacetic acid (MCPA)|94-74-6|Not Assessed under the IRIS program.||||||
-Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI)|101-68-8|.||||||
+Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI)|101-68-8|Hyperplasia of olfactory epithelium|mg /m<sup>3</sup>|6x10<sup>-4</sup>|BMC<sup>10</sup> (HEC)|0.06|Medium|0529
 ,4'-Methylene bis(N,N'-dimethyl)aniline|101-61-1|Not Assessed under the IRIS program.||||||
 Methylmercury (MeHg)|22967-92-6|Not Assessed under the IRIS program.||||||
@@ Line 493: / Line 493: @@
 Monochloramine|10599-90-3|Not Assessed under the IRIS program.||||||
 Naled|300-76-5|Not Assessed under the IRIS program.||||||
-Naphthalene|91-20-3|.||||||
+Naphthalene|91-20-3|Nasal effects: hyperplasia and metaplasia in respiratory and olfactory epithelium, respectively|mg /m<sup>3</sup>|3x10<sup>-3</sup>|LOAEL (HEC)|9.3|Medium|0436
 Napropamide|15299-99-7|Not Assessed under the IRIS program.||||||
 Nickel carbonyl|13463-39-3|Not Assessed under the IRIS program.||||||
@@ Line 503: / Line 503: @@
 Nitric oxide|10102-43-9|Not Assessed under the IRIS program.||||||
 Nitrite|14797-65-0|Not Assessed under the IRIS program.||||||
-Nitrobenzene|98-95-3|.||||||
+Nitrobenzene|98-95-3|Bronchiolization of the alveoli and olfactory degeneration|mg /m<sup>3</sup>|9x10<sup>-3</sup>|BMCL<sub>10</sub> (HEC)|0.26|Medium|0079
 Nitrogen dioxide|10102-44-0|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
 Nitroguanidine|556-88-7|Not Assessed under the IRIS program.||||||
 p-Nitrophenol|100-02-7|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
--Nitropropane|79-46-9|.||||||
+-Nitropropane|79-46-9|Liver focal vacuolization and nodules|mg /m<sup>3</sup>|2x10<sup>-2</sup>|LOAEL (HEC)|16|Low|0519
 N-Nitroso-N-methylethylamine|10595-95-6|Not Assessed under the IRIS program.||||||
 N-Nitroso-di-n-butylamine|924-16-3|Not Assessed under the IRIS program.||||||
@@ Line 544: / Line 544: @@
 Phenylmercuric acetate|62-38-4|Not Assessed under the IRIS program.||||||
 Phosalone|2310-17-0|Not Assessed under the IRIS program.||||||
-Phosgene|75-44-5|.||||||
+Phosgene|75-44-5|Collagen staining indicative of fibrosis|mg /m<sup>3</sup>|3x10<sup>-4</sup>|BMDL<sub>10</sub> (HEC)|0.03|Medium|0487
 Phosmet|732-11-6|Not Assessed under the IRIS program.||||||
-Phosphine|7803-51-2|.||||||
+Phosphine|7803-51-2|Decreased body weight|mg /m<sup>3</sup>|3x10<sup>-4</sup>|NOAEL (HEC)|0.25|Low|0090
-Phosphoric acid|7664-38-2|.||||||
+Phosphoric acid|7664-38-2|Bronchiolar fibrosis|mg /m<sup>3</sup>|1x10<sup>-2</sup>|BMC<sub>10</sub> (HEC)|3.4|Medium|0697
 Phthalic anhydride|85-44-9|Not Assessed under the IRIS program.||||||
 Picloram|1918-02-1|Not Assessed under the IRIS program.||||||
@@ Line 566: / Line 566: @@
 Propiconazole|60207-90-1|Not Assessed under the IRIS program.||||||
 beta-Propiolactone|57-57-8|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
-Propionaldehyde|123-38-6|.||||||
+Propionaldehyde|123-38-6|Atrophy of olfactory epithelium|mg /m<sup>3</sup>|8x10<sup>-3</sup>|BMCL<sub>10</sub> (HEC)|8|Low/Medium|1011
 Propylene glycol|57-55-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
 Propylene glycol monoethyl ether|52125-53-8|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
-Propylene glycol monomethyl ether (PGME)|107-98-2|.||||||
+Propylene glycol monomethyl ether (PGME)|107-98-2|Mild reversible sedation|mg /m<sup>3</sup>|2|NOAEL (HEC)|658|Medium|0404
-Propylene oxide|75-56-9|.||||||
+Propylene oxide|75-56-9|Nest-like infolds of the nasal respiratory epithelium|mg /m<sup>3</sup>|3x10<sup>-2</sup>|LOAEL (HEC)|2.9|Medium|0403
 Propyleneimine|75-55-8|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
 Pursuit|81335-77-5|Not Assessed under the IRIS program.||||||
@@ Line 599: / Line 599: @@
 Strontium|7440-24-6|Not Assessed under the IRIS program.||||||
 Strychnine|57-24-9|Not Assessed under the IRIS program.||||||
-Styrene|100-42-5|.||||||
+Styrene|100-42-5|CNS effects|mg /m<sup>3</sup>|1|NOAEL (HEC)|34|Medium|0104
 Systhane|88671-89-0|Not Assessed under the IRIS program.||||||
 Tebuthiuron|34014-18-1|Not Assessed under the IRIS program.||||||
@@ Line 611: / Line 611: @@
 ,1,1,2-Tetrachloroethane|630-20-6|Not Assessed under the IRIS program.||||||
 ,1,2,2-Tetrachloroethane|79-34-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
-Tetrachloroethylene|127-18-4|.||||||
+Tetrachloroethylene|127-18-4|Not Assessed under the IRIS program.||||||
 ,3,4,6-Tetrachlorophenol|58-90-2|Not Assessed under the IRIS program.||||||
 Tetrachlorovinphos|961-11-5|Not Assessed under the IRIS program.||||||
 Tetraethyl lead|78-00-2|Not Assessed under the IRIS program.||||||
 Tetraethyldithiopyrophosphate|3689-24-5|Not Assessed under the IRIS program.||||||
-,1,1,2-Tetrafluoroethane|811-97-2|.||||||
+,1,1,2-Tetrafluoroethane|811-97-2|Leydig cell hyperplasia|mg /m<sup>3</sup>|8x10<sup>1</sup>|BMC<sub>10</sub> (HEC)|8200|Medium|0656
-Tetrahydrofuran|109-99-9|.||||||
 Thallium (I), soluble salts|Various|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
 Thallium acetate|563-68-8|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
@@ Line 629: / Line 628: @@
 Thiophanate-methyl|23564-05-8|Not Assessed under the IRIS program.||||||
 Thiram|137-26-8|Not Assessed under the IRIS program.||||||
-Toluene|108-88-3|.||||||
+Toluene|108-88-3|Neurological effects in occupationally-exposed workers (other effect:)|mg /m<sup>3</sup>|5|NOAEL (ADJ)|46|High|0118
-,4-/2,6-Toluene diisocyanate mixture (TDI)|26471-62-5|.||||||
+,4-/2,6-Toluene diisocyanate mixture (TDI)|26471-62-5|Chronic lung-function decline|mg /m<sup>3</sup>|7x10<sup>-5</sup>|NOAEL (HEC)|0.002|Medium|0503
 Toxaphene|8001-35-2|Not Assessed under the IRIS program.||||||
 Tralomethrin|66841-25-6|Not Assessed under the IRIS program.||||||
@@ Line 644: / Line 643: @@
 Trichlorocyclopentadiene|77323-84-3|Not Assessed under the IRIS program.||||||
 ,1,2-Trichloroethane|79-00-5|Not Assessed under the IRIS program.||||||
-,1,1-Trichloroethane|71-55-6|.||||||
+,1,1-Trichloroethane|71-55-6|Liver histopathologic changes|mg /m<sup>3</sup>|5|NOEL (HEC)|1553|Medium|0197
-Trichloroethylene|79-01-6|.||||||
+Trichloroethylene|79-01-6|Decreased thymus weight in female B6C3F1 mice (immunotoxicity)|mg /m<sup>3</sup>|0.002|LOAEL (HEC<sub>99</sub>)|0.19|High|0199
+Trichloroethylene|79-01-6|Increased fetal cardiac malformations in Sprague-Dawley rats (heart malformations)|mg /m<sup>3</sup>|0.002|BMDL<sub>01</sub> (HEC<sub>99</sub>)|0.021|High|0199
 Trichlorofluoromethane|75-69-4|Not Assessed under the IRIS program.||||||
 ,4,5-Trichlorophenol|95-95-4|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
@@ Line 652: / Line 652: @@
 ,4,5-Trichlorophenoxyacetic acid (2,4,5-T)|93-76-5|Not Assessed under the IRIS program.||||||
 ,1,2-Trichloropropane|598-77-6|Not Assessed under the IRIS program.||||||
-,2,3-Trichloropropane|96-18-4|.||||||
+,2,3-Trichloropropane|96-18-4|peribronchial lymphoid hyperplasia in male rats|mg /m<sup>3</sup>|0.0003|BMCL (HEC)|0.90|Low|0200
 Tricresol|1319-77-3|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
 Tridiphane|58138-08-2|Not Assessed under the IRIS program.||||||
-Triethylamine|121-44-8|.||||||
+Triethylamine|121-44-8|No observed adverse effects (other effect: Inflammation of the nasal passage)|mg /m<sup>3</sup>|7x10<sup>-3</sup>|NOAEL (HEC)|19.5|Low|0520
 Triethylene glycol monobutyl ether|143-22-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
 Triethylene glycol monoethyl ether|112-50-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||
@@ Line 668: / Line 668: @@
 Vernam|1929-77-7|Not Assessed under the IRIS program.||||||
 Vinclozolin|50471-44-8|Not Assessed under the IRIS program.||||||
-Vinyl acetate|108-05-4|.||||||
+Vinyl acetate|108-05-4|Nasal epithelial lesions|mg /m<sup>3</sup>|2x10<sup>-1</sup>|NOAEL (HEC)|5|High|0512
-Vinyl bromide|593-60-2|.||||||
+Vinyl bromide|593-60-2|Hypertrophy, basophilic and eosinophilic foci, in the liver|mg /m<sup>3</sup>|3x10<sup>-3</sup>|LOAEL (HEC)|7.7|Low|0671
-Vinyl chloride|75-01-4|.||||||
+Vinyl chloride|75-01-4|Liver cell polymorphism|mg /m<sup>3</sup>|1x10<sup>-1</sup>|NOAEL (HEC)|2.5|Medium|1001
 Warfarin|81-81-2|Not Assessed under the IRIS program.||||||
 White phosphorus|7723-14-0|Not Assessed under the IRIS program.||||||
-Xylenes|1330-20-7|||||||
+Xylenes|1330-20-7|Impaired motor coordination (decreased rotarod performance)|mg /m<sup>3</sup>|0.1|NOAEL (HEC)|39|Medium|0270
 Zinc and Compounds|7440-66-6|Not Assessed under the IRIS program.||||||
 Zinc cyanide|557-21-1|Not Assessed under the IRIS program.||||||

Difference between revisions of "IRIS"

Revision as of 14:26, 27 June 2012

Contents

Short description

Long description

Link

Key words

Data scrapping

Oral RfDs

Inhalation RfCs

Inhalation unit risks

References

Related files

Navigation menu

Personal tools

Namespaces

Variants

Views

More

Search

Navigation

Page Tools

Tools

In other websites